 
 
GC P# 03.01.020   Date : August [ADDRESS_668109]® Single CBU Protocol   Page [ADDRESS_668110]®, Umbilical Cord Blood -derived Ex 
Vivo Expanded Stem and Progenitor Cells, in Adolescent  and Adult Patients with 
Hematological Malignancies  
 
Study Chair s 
Mitchell Horwitz, MD    Guillermo F. Sanz, MD PhD  
Duke University Medical Center   Hospi[INVESTIGATOR_331179] y Politecnico La Fe  
 
 
Clinical Phase    Phase I/II  
 
Product:     NiCord® 
 
IND Number:     [ADDRESS_668111] Number:    2014 -000074 -19 
 
Sponsor   
Gamida Cell Ltd.  
[PO_BOX]  
Jerusalem [ZIP_CODE]  
Israel  
Tel: 972 -2-6595666  
Fax:  972-2-6595616  
 
Director, Medical Affairs    Einat Galamidi Cohen, M.D.  
Protocol No.     GC P #03.01.020  
Amendment #     V 
Dated                                                August 24, 2015  
       
 
This clinical study will be conducted in accordance with the Sponsor's Standard 
Operating Procedures (SOPs), this protocol, current Good Clinical Practice (GCP), the 
Declaration of Hels inki, the provisions of International Conference on Harmonization 
(ICH) Guidelines and all local applicable laws and regulations.  
 
 
CONFIDENTIAL  
The information in this document is considered privileged and confidential, and may not 
be disclosed to others except to the extent necessary to obtain Institutional Review Board 
(IRB)/Ethics Committee (EC) approval, written informed consent and the approval of 
local regulatory authorities as required by [CONTACT_1769].   
 
 
GC P# 03.01.020   Date : August [ADDRESS_668112]® Single CBU Protocol   Page 2 
 
 
Table of Contents  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668113]® Single CBU Protocol   Page 3 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668114]® Single CBU Protocol   Page 4 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668115]® Single CBU Protocol   Page 5 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668116]® Single CBU Protocol   Page 6 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668117]® Single CBU Protocol   Page 7 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668118]® Single CBU Protocol   Page 8 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668119]® Single CBU Protocol   Page 9 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668120]® Single CBU Protocol   Page 10 
 
  
  
  
  
  
  
  
  
  
  
  
 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668121]® Single CBU Protocol   Page 11 
 
SPONSOR PROTOCOL APPROVAL PAGE  
 
Protocol Title:   Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord 
Blood -derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult 
Patients with Hematological Malignancies  
 
 
Clinical Phase    Phase I/II  
 
 
Protocol Number:     GC P #03.01.020  
 
 
 
Approved by:  
 
[INVESTIGATOR_40373], Medical Affairs  
 
Einat Galamidi Cohen, M.D.  
 
 
 
___________________________________   ___________________________  
Signature       [CONTACT_331299] P# 03.01.020   Date : August [ADDRESS_668122]® Single CBU Protocol   Page 12 
 
 
Protocol Title:   Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord 
Blood -derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult 
Patients with Hematological Malignancies  
 
 
Clinical Phase    Phase I/II  
 
 
Protocol Number:     GC P #03.01.020  
 
1. INVESTIGATOR’S AGREEMENT  
I have carefully read the foregoing protocol including all appendices and agree that it 
contains all the necessary information for conducting the study safely.  
I will conduct this study in strict accordance with this protocol and according to the 
current GCP regulations and will attempt to complete the study within the time 
designated.  
 
I will provide copi[INVESTIGATOR_331160] -clinical and 
prior clinical experience submitted by [CONTACT_515632]. I will discuss this information with them to ensure that they are 
adequately informed regarding the drug and conduct  of the study.  
 
I agree to keep records on all subject information (CRFs, shipment, and all other 
information collected during the study) in accordance with the current GCP and local 
regulations.  
 
  
Principal Investigator’s Name   
 
  
[CONTACT_515665] P# 03.01.020   Date : August [ADDRESS_668123]® Single CBU Protocol   Page 13 
 
2. STUDY SYNOPSIS  
Protocol Number  
GC P # 03.01.[ADDRESS_668124]®, Umbilical Cord Blood -derived Ex 
Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients with 
Hematological Malignancies  
 
Number of Centers and Planned Geographical Distribution  
Multicenter, multinational  
 
Clinical Phase  
Phase I/II  
 
Inve stigational Product    
NiCord® is a cryopreserved stem/progenitor cell based product _____________________  
________________________________________________________________________
________________________________________________________________________
_____ ___________________________________________________________________
________________________________________________________________________
__________________________________________________________ kept frozen until 
they are infused on the  day of transplant ation.  
Study Duration  
Total study duration per patient is approximately [ADDRESS_668125]®: single ex -
vivo expanded cord blood unit  transplantation in patients with hematological 
malignancies following myeloablative therapy as follows:  
Primary Objective s 
• Assess  the cumulative incidence  of patients with  NiCord®-derived neutrophil 
engraftment at 42 days  following  transplantation .  
• Assess the incidence of secondary graft failure at [ADDRESS_668126]® 
 
 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668127]® Single CBU Protocol   Page 14 
 
Secondary Objectives  
• Time from infusion to neutrophil engraftment  
• Time from infusion to platelet engraftment  
• Incidence of platelet engraftment at 100 days   
• Proportion of non-relapse mortality at 100 days  
• Incidence of  acute GvHD grade II -IV and III -IV at 100 days  
• Incidence of chronic GvHD (limited or extensive) at 180 days and 1 year  
• Incidence of secondary graft failure at [ADDRESS_668128]® 
• Overall  survival at 180 days and 1 year  
• Safety and tolerability of NiCord® transplantation  
 
Exploratory Objectives   
• Immune reconstitution at 70, [ADDRESS_668129]® following myeloablative conditioning in  patients with 
hematological malignancies  will provide sustained engraftment.  
Study Design   
This is an open -label, non -randomized, interventional, single group assignment study of 
NiCord® in adolescent and adult patients suffering from hematological malign ancies . 
Once an optimally matched CBU  has been identified  and the patient (or legal guardian ) 
signed the informed consent (IC), the patient will be screened for the study. 
________________________________________________________________________
____________ ____________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________________________________ ____________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________ ____________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________________________________________ ____________
________________________________________________________________________
_______________________________________________________________________ _
________________________________________________________________________
 
 
GC P# 03.01.020   Date : August [ADDRESS_668130]® Single CBU Protocol   Page 15 
 
____________________________ ____________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________________________________________________ ____
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________________ ____________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____ ____________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________________________ ____________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________ ____________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________________________________ ____________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________ ____________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________________________________________ ____________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________ ____________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________________________________________________ ____
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________________ ____________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____ ____________________________________________________________________
________________________________________________________________________
 
 
GC P# 03.01.020   Date : August [ADDRESS_668131]® Single CBU Protocol   Page [ADDRESS_668132] be 12-65 years of age  
2. Patients with one of the following hematologic malignancies:  
▪ ____________________________________________________  
a. _________________________________________________________
_________________________________________________________  
▪ ______________________________________________________
________ ____________  
▪ ____________________   
▪ ___________________ ___________________________________
________________________ _ 
b. ____________________________  
i. ____________________________________________________  
a. _________________________________________________________
_____________________________  
__________________________________________________  
▪ _____________________________________  
▪ _____________________________________  
▪ ______________________________________________________
_________________  
▪ __________________________________________________  
▪ ______________________________________________________  
b. _______________________________________  
▪ ____________________________________________________  
a. __________________________________________________  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668133]® Single CBU Protocol   Page 17 
 
▪ ______________________________________________________
______________________________________________________
________  
▪ ___________________________________ ______________  
▪ _______________________  
b. _________________________________________________________  
▪ ______________________________________________________
______________  
▪ _____________________________________________  
c. _________________________________________________________
_____________  
▪ ____________________________________________________________
____________________________________________________________
____________________________________________________________
_____ _______________________________________________________
__________________________  
____________________________________________________________
____________________________________________________________
______________________________________________________ ______
__________________________________________________________  
____________________________________________________________
____________________________________________________________
____________________________________________________________
___________ _______________________________________________  
▪ ____________________________________________________  
3. _________________________________________________________________
_________________________________________________________________
_________________________ ________________________________________
__________________________________________  
▪ ____________________________________________________  
4. _________________________________________________________________
_______________________________________________________ __________
_________________________________________________________________
__________________________________________ .  
▪ ____________________________________________________  
▪ ____________________________________________________  
______________________________ __________________________________________
________________________________________________________________________
 
 
GC P# 03.01.020   Date : August [ADDRESS_668134]® Single CBU Protocol   Page 18 
 
________________________________________________________________________
_____________________  
5. ________________________________________________ _________________
_________________________________________________________________
_________________________________________________________________
__________________________________________  
▪ ____________________________________________________  
6. _____________ ____________________________________________________
________________________________________  
 
Exclusion Criteria  
 
1. __________________________________  
2. _______________________  
3. _____________________________________  
4. __________________________________  
5. __________________________________________________________________
__________________________________________________________________
__________________________________________________________________
_______________________ ___________________________________________
_________________________________________  
 ____________________________________________________  
6. ______________________________________________________________  
7. _______________________________________________________  
8. __________________________________________________________________
_______________________________________________  
 ____________________________________________________  
 ____________________________________________________  
9. ___________________________________ _______________  
__________________________________________________________________
__________________________________________________________________
____________________________________________ .   
 ____________________________________________________  
10. ,______ __________________________________________  
__________________________________________________________________
_________________________   
 ____________________________________________________  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668135]® Single CBU Protocol   Page 19 
 
11. __________________________________________________________________
__________________________________________________________________
______________________________________  
 ____________________________________________________  
12. __________________________________________________________________
_________________________________ _________________________________
______________________________________  
13. __________________________________________________________________
__________________________________________________________________
______________________________________  
 __________________________________________________ __________
___________ __ 
 ____________________________________________________  
 ____________________________________________________  
 ____________________________________________________  
 _______________________ _____________________________  
 
Statistical Considerations   
The sample size for the study was not determined by [CONTACT_515633].  
Descriptive statistics will be applied to the results of all data from primary and secondary 
assessment.  
Primar y End -point and Principal Analysis :  
Neutrophil engraftment is defined as achieving an absolute neutrophil count (ANC) 
greater than or equal to 0.5 x 109/L on 3 consecutive measurements on different days with 
donor chimerism ( < 10% host cells by [CONTACT_515634]) within [ADDRESS_668136] of the 3 
consecutive measurements.  
Secondary graft failure consists of documented neutrophil engraftment, followed by 
[CONTACT_515635] (< 0.5 x 109/L for three or more consecutive laboratory values  on 
separate days ) with marrow cellularity <5%, without subsequent improvement occurring 
either spontaneously or after growth factor treatment.  
Interim Analysis and Safety Assessment Guidelines :  
The data emerging from this study will be reviewed by [CONTACT_3153]. This 
committee will review the accumulated data after [ADDRESS_668137] been assessed at day 100 following the transplant. A 4th patient may be transplanted 
prior to DMC review.  At this initial review,  the DMC will monitor  in particular: any 
occurrence of primary or secondary graft failure, as well as any substantial decrease in 
donor chimerism (especially myeloid chimerism), or evid ence of impending graft failure, 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668138]® Single CBU Protocol   Page [ADDRESS_668139] recipi[INVESTIGATOR_841].   The committee will make recommendations to the Sponsor regarding 
early stoppi[INVESTIGATOR_331167].  
________________________________________________________________________
_______________________ _________________________________________________
_____________________________________________________________  
▪ _____________________ :  
  
  
  
  
  
  
  
  
  
  
  
 
▪ _______________________________ :  
  
  
  
  
  
  
  
  
  
  
  
 
▪ ____________________________ :  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668140]® Single CBU Protocol   Page [ADDRESS_668141] to the overall study enrollment, then further 
use of that conditioning regimen will be prohibited until the DMC  review s the data and 
provide s recommendations to the Sponsor regarding further use or modification of the 
conditioning regimen.   
__________ ________   
________________________________________________________________________
__________________________________ ______________________________________
___________________________________ : 
i. __________________________________________________________________
________________________________________________________________  
ii. __________________________________________________ ________________
__________________________________________________________________
_________________________________________  
iii. __________________________________________________________________
__________________________________________________________________
__________________________________________________  
 
 
GC P# 03.01.020  Date: August [ADDRESS_668142]® Single CBU Protocol  
Figure  1:  Study Scheme  
 

 
 
GC P# 03.01.020  Date: August [ADDRESS_668143]® Single CBU Protocol   Page 23 
 
3. INTRODUCTION  
3.1. Overview  
Successful blood and marrow transplant ation  (BMT) requires the  infusion of a sufficient 
number of hematopoietic stem /progenitor cells (H SPCs) , capable of  both homing to the 
bone marrow and regenerating a full array of hematopoietic cell lineages  with early and 
late repopulating ability in a timely fashion(Cottler -Fox[1],. 
Despi[INVESTIGATOR_515603], less than 50% 
of unrelated donor searches result in identification and availability of a suitably matched 
donor graft. Donor searches for recipi[INVESTIGATOR_16483]-Northern -European descent  result in 
even lower success . Umbilical cord blood (UCB) is an alternative stem cell source for 
hematopoietic stem cell transplantations (HSCT) and is clinically in use  for the treatment 
of diverse life -threatening diseases, such as hematological malignan cies or genetic blood 
disorders . UCB grafts have been used in over 20,000 stem cell transplant recipi[INVESTIGATOR_515604] a matched related or unrelated 
stem cell donor are unavailable . There are numerous adva ntages to UCB as a 
transplantable graft source. These include the ease of procurement, the absence of risk to 
the donor, the reduced risk of transmissible infections, and the availability for immediate 
use, potentially reducing  a long wait and risk of disease progression - particularly 
important for patients with acute leukemia[Wagner 2009[ 2]; Aljitawi 2012[ 3] ]. However, a major 
drawback of UCB is the low stem cell dose available for transplantation, compared to 
mobilized  peripheral blood (PB) or bone marrow[Aljitaw 2012[ 3]]. This low stem  cell dose can 
compromise the chances of  engraftment and c ontribute s to delayed kinetics  of neutrophil 
and platelet recovery (Yamazaki, Kuwana et al. 2006[ 4]). The delay in graft function may negatively 
impact transplant outcome [Brunstein, Gutman et al. 2010 [ 5] ; Ramirez, Brunstein et al. 2010[ 6]] and prolong 
the duration of hospi[INVESTIGATOR_515605].   
The transplant community ha s been actively engaged in developi[INVESTIGATOR_515606] (CBT), which is most acute in adolescent 
and adult recipi[INVESTIGATOR_840]. Several approaches were developed, including dual umbilical cord 
blood transplantation  (DCBT) and ex vivo  expansion of UCB stem cells. Although to date 
no prospective clinical trials on the efficacy of single cord versus double cord in adults 
have been published, the DCBT has become standard practice in CBT for recipi[INVESTIGATOR_515607] a single C BU of adequate cell dose is unavailable.[ Cottler -Fox [1], MacMillan, Weisdorf et al. 
2009 [ 7]; Brunstein, Gutman et al. 2010[ 5]; Ramirez, Brunstein et a l. 2010[ 6]; Stanevsky, Shimoni et al. 2010[ 8]] Ex vivo  
expansion is still an experimental approach.  Published data of clinical studies evaluating 
this approach are discussed in section 3. 2.  
NiCord® is a stem/progenitor cell -based product composed of ex vivo  expanded 
allogeneic cells from one entire unit of UCB. NiCord® was developed based on the 
finding that Nicotinamide (NAM), a form of vitamin B3, delays differentiation and 
increase s functionality of ex vivo  expanded hematopoietic progenitor cells. Pre -clinical in 
 
 
GC P# 03.01.020  Date: August [ADDRESS_668144]® Single CBU Protocol   Page 24 
 
vitro  and in vivo  studies performed by [CONTACT_515636]34+ cells in a NAM -containing culture system  increases the fraction of e arly  
stem/ progenitor cells within the expanded cell graft, and augments bone marrow homing 
and engraftment. Based on these results the Sponsor believes that NiCord® has the 
potential to enable broader application and improvement of clinical outcomes of UC B 
transplantation.   
The chief aim of the proposed study is to evaluate the safety and efficacy of NiCord® 
transplantation in a single c ord blood unit (CBU) study in  patients with hematological 
malignancies . 
Currently, NiCord® is being investigated in two pi[INVESTIGATOR_515608] a DCBT configuration, as 
described in Section 3.5 (the first study has been completed) . In these pi[INVESTIGATOR_7602], the 
DCBT platform  serve s as a model to evaluate  both the safety of use of a manipulated  
graft and enables the simultaneous tracking of the contribution of NiCord® to short - and 
long-term hematopoietic recovery  and its relative contribution to the myeloid and 
lymphoid hematopoietic lineages reconstitution . 
The study GC P#01.01.[ADDRESS_668145]®. 
The study GC P#02.01.[ADDRESS_668146]®.  Both of these studies are evaluating the 
safety and efficacy of NiCord® transplantation in combination w ith a second, 
unmanipulated CBU in patients with hematological malignancies or sickle cell disease, 
respectively.   
3.2. The Use of DCBT and Ex -Vivo Expansion  to Over come the Cell 
Dose Limitation in CBT  
The following section provides a review of literature describing the advantages and 
disadvantages of the DCBT modality  and published data describing the expansion 
technologies evaluated in DCBT studies.  
The DCB T approach is now standard practice for adolescent and adult recipi[INVESTIGATOR_515609] a single UCB of adequate size is unavailable . Phase II non -comparative studies , 
and retrospective comparisons,  suggest that by [CONTACT_1583] a second CBU, successful 
engraftment can be achieved at a rate that is comparable to a UCB transplantation using a 
single adequately sized CBU[(Verneris, Brunstein et al. 2009 [9]]. Transplant -Related Mortality  
(TRM)  and o verall survival appear to be  comparable in single and double CBT 
modalities . The use of DCBT  as a transplant modality has been shown to possibly reduce 
the risk of relapse in patients with less advanced leukemia[ Stanevsky, Shimoni et al. 2010 [8]; Sideri, 
Neokleous et al. 2011 [10]]; however this may be associated with  a slight increase in the risk of 
graft -versus -host disease (GvHD)[ (Verneris, Brunstein et al. 2009 [9]].  Viabi lity of UCB stem cells 
is a prerequisite for successful engraftment. Adequate viability cannot be confirmed until 
the CBU is thawed on the day of transplantation. The DCBT approach increases the 
chance that a highly viable CBU is provided to the patient[ Scaradavou, Smith et al. 2009 [11]].  
Importantly, despi[INVESTIGATOR_331173], time -to-neutrophil and 
 
 
GC P# 03.01.020  Date: August [ADDRESS_668147]® Single CBU Protocol   Page 25 
 
platelet engraftment (engraftment k inetics) and engraftment rates appear to be 
comparable between single and double CBT[ Sideri, Neokleous e t al. 2011 [10]].  Thus  the use of 
DCBT does not appear to improve the hematopoietic recovery following transplantation.  
Another confounding topic to consider is that i n DCBT usually only one of the two CBU s 
engraft s. Early after transplantation  (day 21) both CBUs  contribute to  hematopoiesis in 
40–50% of patients, but by [CONTACT_4475] 100, one CBU  predominates in the vast majority of 
patients .[ Ramirez, Wagner et al. 2012 [12]] The mechanism of single donor dominance is likely to be 
multi -factorial, involving intrinsic features of the CBUs  such as homing properties and 
proliferative potential  of the stem cells, graft -graft interactions mediated by T -cell 
interactions, as well as  host-graft interactions. No reproducible association has been 
found between CBU  characteristics such as median infused total nucleated cells ( TNC ), 
CD34+, and CD3+ cell doses and unit dominance[ Majhail , Brunstein et al. 2006 [13]], therefore the 
dominant CBU  cannot yet be predicted. It has been postulated that graft -versus -graft 
immune interactions are the principal mechanism promoting the engraftment of a single 
CBU in patients undergoing DCBT. Delaney et al[ Newell , Milano et al. 2012 [14]] have 
demonstrated that early CD3+ PB chimerism predicts the long -term engrafting CBU  
following myeloablative DCB T. The correlation of higher early post -transplant donor 
CD3+ PB chimerism with the dominant CBU  suggests  a rapid immune mediated response 
as a primary mechanism of action for long -term single donor dominance. In vivo[ Eldjerou, 
Chaudhury et al. 2010 [15]] and in vitro[ Moretta , Andriolo et al. 2012 [16]] studies also suggest that the 
predominant CB U in the setting of double CBT is the CBU  able to develop a prevalent 
cytotoxic activity directed against activated lymphocytes and HSC graft of the other 
CBU. The time needed for the predominant CB U to overcome the other CBU  in vivo  
could depend on the degree of reciprocal alloantigen -specific c ytotoxic potency of the 
two CB Us. It is therefore possible that a discordant dominance between the two CB Us, in 
terms of stem cell potency and graft -versus -graft alloreactivity, could result in graft 
failure, i.e. when the dominant CBU with respect to allo reactive capacity eradicates the 
CBU able to support a more efficient and robust hematopoietic engraftment[ Moretta, Andriolo 
et al. 2012 [16]].  
Ex vivo  expansion was suggested as a modality to increase the numbers and/or potency of 
cells in a single CBU  and to enhance the efficacy and applicability of CBT[(Kelly , Parmar et al. 
2010 [17]; Dahlberg [18], Delaney  et al. 2011 [19]; Aljitawi 2012 [3]] . This has prompted intensive research and 
development of novel and more potent expansion technologies.   
DCBT  serves as a model to evaluate novel graft manipulations[Wagner 2009  [2]] not only 
adding a measure of safety (with an unmanipulated CBU ) but by [CONTACT_515637] - and long -term hematopoietic 
recovery[Ramirez, Wagner et al. 2012 [12]]. Two studies reported so far describe the transplantation 
of ex vivo  expanded cells from one CBU in combination with a second non -manipulated 
CBU[De Lima , Robinson et al. 2010 [20]; De Lima  et al. 2012  [21]; Delaney, Heimfeld et al. 2010  [19]]. In their 
publication s they show that the  expanded cells contributed mainly  to initial myeloid 
engraftment that occurred at a median time of about [ADDRESS_668148] before or after engraftment, while the 
unmanipulated CBU took over  in all of the recipi[INVESTIGATOR_840]. A lack of in vivo  persistence of the 
 
 
GC P# 03.01.020  Date: August [ADDRESS_668149]® Single CBU Protocol   Page [ADDRESS_668150]® as a single expanded 
CBU  
Ideally, a successful expansion technology would obviate the need for D CBT, and in 
most cases would enable the clinician  to choose a single , best HLA -matched CBU for the 
patient . Most ex vivo  expansion technologies are successful in expanding a subset of 
hematopoietic progenitor cell s (HPCs), which  are expected to improve short -term early 
hematopoietic reconstitution ; while the main concern still remains for preservation of 
long-term repopulating cells in ex vivo  conditions[ Srour, Abonour et al. 1999  [22]; Ando , Yahata et al. 2006 
[23]; Drake , Khoury et al. 2011 [24]] . The concern is not only related to the p ersistence of such 
unique cells in culture , but also to their potential to differentiate and reconstitute all blood 
cell lineages including myeloid, T, NK and B cells , as efficiently as the long -term 
repopulating cells before expansion[ Holmes , Yan et al. 2012 [25]].  
Until the advent of NiCord® expansion technology, ex vivo  expansion studies have only 
been successful in demonstrating short -term early hematopoietic reconstitution.  
In light of the accumulated data from both the literature described  in section 3.[ADDRESS_668151]® technology  is feasible and provides sustained donor -derived 
engraftment in  adult patients with hematological malignancies  following myeloablative 
therapy .  
The clinical outcomes  of patients with hematological malignancies  transplanted with 
NiCord®, delivered as part of a DCBT approach, demonstrate that eight out of eleven 
patients engrafted with a myeloid predominance of the expanded CBU ( NiCord®) and 
those eight patients achieved neutrophil and platelet  engraftment  at a median of [ADDRESS_668152] -transplantation, respectively ( Table 2 ). Based on the last chimerism t ests 
performed the  expanded cells are shown to persist in all eight patients initially engrafted 
with NiCord® (Table 3 ). In five out of eight patients, both myeloid and lymphoid cells 
derived entirely from the NiCord® graft (Table 3 ). Immune reconstitution analysis of 
these patients last performed at days 100, [ADDRESS_668153]-transplantation also 
demonstrated the recovery of all blood cell lineages including CD3, CD4 and CD8 (T 
cells), CD19 (B cells) and CD56 (NK cells) ( Table 4 ). The pattern of immunologic 
reconstitution of all blood cell lineages appears to be comparable between patients who 
engrafted with NiCord® only and  patients who engrafted with the unmanipulated unit 
only ( Table 4 ). At a median follow -up of 364 days after trans plantation  (range 100-404), 
9 of 11 transplanted patients are alive with no reported secondary graft failure .  
The DCBT approach adds a measure of safety to the evaluation of novel approaches to ex 
vivo expansion . However, as previously described, the draw back of this strategy is that 
 
 
GC P# 03.01.020  Date: August [ADDRESS_668154]® Single CBU Protocol   Page [ADDRESS_668155]® may make it 
possible to choose the best CBU  for the patient , expand it in culture and transplant it to 
the patient in a single CBT approach.  As detailed in section 3.6, the study has been 
designed to assess the use of NiCord® in a single CBT  configuration  while maintaining a 
careful monitoring of patient safety. Thu s, prohibitive cell dose requirements will be 
applied, both to the CBU selection, and to the NiCord® product when administered as a 
single CBT. The primary endpoints focus on the risk of graft failure, both in the short and 
long term. Moreover, strict stop pi[INVESTIGATOR_515610].  
Demonstration of successful, rapid and sustained engraftment of a single expanded CBU 
would obviate the need for the use of a second CBU, providing both potentially less 
GvHD and significant cost saving s. NiCord® could potentially provide an alternative graft 
for unrelated donor transplantation in patients who do not have a matched adult donor 
option, thereby [CONTACT_199740] a critical unmet need in the treatment of hematologic 
malignancies.  
The manufacturing  of the fresh and the cryopreserved NiCord® cultured fraction is 
exactly the same apart for the re -suspension on the last manufacturing day.  The 
cryopreservation of NiCord® allows flexibility in the planning and timing of 
transplantation, to accommodate the patient’s disease status and any changes required, as 
resulting from the patient’s medical condition.  
3.4. Gamida Cell Expansion Technology  
NiCord® is composed of CB -derived allogeneic stem and progenitor cells expanded ex  
vivo from an entire CB U with cytokines and nicotinamide, a form of the vitamin B3. 
________________________________________________________________________
________________________________________________________________________
____________________________________________  
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________ ___________   ___ . 
The expansion technology is based on the finding that nicotinamide epi[INVESTIGATOR_515611].  
Engraftment i s a multi -step process involving directed migration of the inoculated cells,  
homing to the BM, retention within the BM niche followed by [CONTACT_6270]-renewal  and 
differentiation.  Engraftment efficacy following expansion is known to be low due to 
poor homing to the bone marrow compared to fresh CD34 + cells (Szilvassy 1999 [26]; Ahmed, Ings et 
al. 2004 [27]; Foguenne 2005 [28]) or reduced self -renewal owing to enhanced differentiation in 
culture.  
 
 
GC P# 03.01.020  Date: August [ADDRESS_668156]® Single CBU Protocol   Page 28 
 
Therefore, the goal of the ex vivo expansion of hematopoietic progenitor cells (HPC) is  
to increase their numbers while maintaining their self -renewal capacity and their ability  
to home to the bone marrow (BM) and efficiently re constitute hematopoiesis. Exposure  
of HPC to different combinations of cytokines promotes their exit from the G0 phase of  
the cell cycle and enables extensive proliferation. Nonetheless, in vitro proliferation is  
tightly coupled with commitment to differen tiation, and reduced self -renewal  (Von Drygalski,  
Alespeiti et al. 2004 [29]). Exposure to early -acting cytokines (SCF, TPO, FLT3 and IL6) induces  
robust in vitro expansion of CD34 + cells, but expansion of engraftable progenitors is  
modest  (Xu and Reems 200 1[30]). This discrepancy could be explained, at least in part, by [CONTACT_515638]  (Szilvassy 1999 [26]; 
Szilvassy,  Meyerrose et al. 2000 [31]), which is primarily attributed to their active cycling  (Takatoku, Sellers 
et al. 2001 [32]) accompanied by [CONTACT_515639] r expression or  
functionality  (Ahmed, Ings et al. 2004  [27]). Strategies to augment the BM homing and 
engraftment efficacy are particularly important to increase clinical applicability of ex 
vivo expanded  CD34 + cells (Hofmeister 2007 [33]). 
Gamida Cel l extensive studies discovered that NAM delays differentiation and increase s 
the engraftment efficacy of cord -blood derived, purified CD133 + cells cultured with a  
combination of 4 -cytokines (FLT3, SCF, TPO and IL6) for 19 -23 days. In the presence of  
NAM th e fraction of CD34 +CD38 - early progenitor cells increase s and the fraction of  
differentiated myelomonocitic cells (CD14 +, CD11b +, CD11c +) decrease s over cytokines  
alone treated cultures. CD34 + cells cultured with NAM displayed increased migration  
towards SDF -1 and home to the bone marrow (24hr post infusion) with higher efficacy  
than cells cultured with cytokines only or non -cultured cells  (Peled 2012 [34]). 
________________________________________________________________________
____________________ ____________________________________________________
________________________________________________________________________
_________________________________________   
________________________________________________________________________
_________________ _______________________________________________________
________________________________________________________________________
________________________________________________________________________
_________________________________________________________ _______________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
_________________________ ___________________________  
NAM serves as a precursor of nicotinamide adenine dinucleotide (NAD +) (Berger, Ramirez -
Hernandez et al. 2004 [35]). On the other hand, NAM is a potent inhibitor of enzymes that require  
NAD + for their activity (Banasik, Komura et al. 1992 [36]; Corda and Di Girolamo 2003 [37]), such as mono -
ADPribosyltransferases  (mARTs), poly -ADP -ribose polymerases (PARPs) and CD38,  
cADPR/NADase  (Krebs, Adriouch et al. 2005 [38]). Having multiple effects on numerous cells, 
NAM is  implicated in regulation of cell adhesion, polarity, migration, proliferation and  
differentiation  (Glowacki, Braren et al. 2002 [39]). NAM was shown to modulate the fate of 
embryonic  stem cells  (Papaccio, Ammendola et al. 1999 [40]) and of primary non -hemato poietic cells  
 
 
GC P# 03.01.020  Date: August [ADDRESS_668157]® Single CBU Protocol   Page 29 
 
(Papaccio, Ammendola  et al. 1999; Sato, Mitaka et al. 1999 [41]; Miura and Kameda 20 05[42]). On hematopoietic cell 
lines it has dual effects;  on the one hand it inhibits HL -60 cell differentiation mediated by 
[CONTACT_281282],  (Munshi, Graeffet al. 200 2[43]) and on the other hand it directly drives HL -60 cell 
differentiation  (Iwata, Ogata et al.  2003 [44]). 
NAM has also been demonstrated as a strong noncompetitive inhibitor of SIRT1, the  
NAD -dependent class III histone deacetylase  (Denu 2005 [45]). In lower eukaryotes, Sir2 (the  
mammalian SIRT1 homolog) has been strongly implicated in the modulation of  
replicative lifespan and promotion of longevity while NAM strongly inhibits silencing  
and shortens replicative life span  (Bitterman, Anderson et al. 2002 [46]). 
In contrast to its function in lower eukaryotes, SIRT1 function in higher eukaryotes is  
still debatable  (Vaca, Berna et al. 2003 [47]). A growing body of evidence suggests SIRT1 to inhibit  
proliferation and to promote differentiation of mammalian cells , and NAM , through  
inhibition of SIRT1 , to inhibit their differentiation  (Blander, Bhimavarapu et al. 2008 [48]; Kim, Ahn et al. 
2009 [49]). Our studies show that EX -527, a specific inhibitor of SIRT1 catalytic activ ity, 
inhibits  differentiation of culture expanded CD34 + cells similar to NAM. NAM positional  
isomers, NAM -related molecules or NAM non -related PARP and mARTs inhibitors did  
not inhibit differentiation, suggesting SIRT1 as the primary target of NAM -modulati ng 
differentiation of cultured CD34 + cells (Peled 2012) . 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________ ________________________________
________________________________________________________________________
________________________________________________________________________
_______________________________________  
3.5. Clinical Experience  
Currently  NiCord® is being investigated in two pi[INVESTIGATOR_515608] a DCBT configuration, as 
summarized in Table 1 below . 
Table  1:  Overview of Ongoing Clinical Studies of NiCord® 
Protocol Number 
(ClinicalTrials.gov 
Number)  Study Title Study 
Status  Institution / Principal 
Investigator  
[CONTACT_27199] P#01.01.020  
([STUDY_ID_REMOVED]a) Allogeneic Stem Cell Transplantation of 
NiCord®, Umbilical Cord Blood -Derived Ex 
Vivo Expanded Stem and Progenitor Cells, in 
Combination With a Second, Unmanipulated 
Cord Blood Unit in Patients With 
Hematological Malignancies   
Complete  Duke University Health 
System/  
[CONTACT_331303] and 
[CONTACT_515667], Loyola University/  
[CONTACT_331305]  
 
 
GC P# 03.01.020  Date: August [ADDRESS_668158]® Single CBU Protocol   Page 30 
 
Protocol Number 
(ClinicalTrials.gov 
Number)  Study Title Study 
Status  Institution / Principal 
Investigator  
[CONTACT_27199] P#02.01.020  
([STUDY_ID_REMOVED]b) Allogeneic Stem Cell Transplantation of 
NiCord®, Umbilical Cord Blood -Derived Ex 
Vivo Expanded Stem and Progenitor Cells, in 
Combination with a Second, Unmanipulated 
Cord Blood Unit in Patients with Sickle Cell 
Disease  Ongoing  Duke University Health 
System/  
[CONTACT_515668]’s Medical 
Center of [LOCATION_001]/  
[CONTACT_515669]  
 http://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=nicord&rank =1.  
 http://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=[STUDY_ID_REMOVED]&rank=1 .  
The subsequent sections describe the clinical studies mentioned above. The preliminary 
clinical da ta provided in Tables 2 -5 are updated as of December 17, 2013 . 
3.5.1.  Study GC P#01.01.020  
A pi[INVESTIGATOR_799] ( GC P#01.01.020 ), entitled: “Allogeneic Stem Cell Transplantation of 
NiCord®, Umbilical Cord Blood -derived Ex Vivo  Expanded Stem and Progenitor Cells, in 
Comb ination with a Second, Unmanipulated Cord Blood Unit in Patients with 
Hematological Malignancies” has been completed  at Duke University Medical Center, 
NC, [LOCATION_003]  and Loyola University Cardinal Bernardin Cancer Center,  IL, [LOCATION_003] . The study 
evaluat ed the transplantation of NiCord® in combination with an unmanipulated CB U, for 
the hematopoietic support of subjects with hematological malignancies  receiving high -
dose chemotherapy.  
As of December 17, [ADDRESS_668159]®. The conditioning regimen consist ed of total body irradiation (TBI) 
1350 cGy fractionated to nine doses and fludarabine 160 mg/m2. Two patients al so 
received cyclophosphamide 120 mg /kg. 
Study  results show  a 16-186 fold enrichment in the numbers of CD34+ cells infused 
following expansion, compared to the CD34+ cell dose in the CBU post -thaw. Ten out of 
eleven patients transplanted with NiCord® have experienced donor hematopoietic 
engraftment. In all eleven  patients (including the non -engrafting patient), day seven PB 
chimerism demonstrated predominance of the NiCord® expanded CBU. Eight patients 
have engrafted with a myeloid predominance of the expanded CBU ( NiCord®). As of 
December 17, [ADDRESS_668160] in  all eight patients  that were 
initially engrafted with the  expanded CBU (Table 3) . These eight patients achieved 
neutrophil engraftment at a median of 10 .5 days after transplantation (range 7 -18 days), 
and platelet engraftment at a median of 31.5 days after transplantation (range [ADDRESS_668161] transplant ). 
Within the eight patients engrafted with a myeloid predominance of the expanded CBU ; 
one patient engrafted with myeloid cells from both NiCord® and the unmanipulate d CBU 
and CD3 c ells from the unmanipulated CBU, t wo patients engrafted with myeloid cells 
 
 
GC P# 03.01.020  Date: August [ADDRESS_668162]® Single CBU Protocol   Page [ADDRESS_668163]® only and CD3 cells from both Ni Cord® and the unmanipulated CBU,  five 
patients engrafted with NiCord® alone.  
Based on the last chimerism (total PB, myelo id-CD15 and lymphoid -CD3) follow -up at 
days [ADDRESS_668164]® (Table 3) . In addition to myeloid recovery, the patients who are 
fully engrafted with the expanded CBU also demonstrate robust recovery of lymphoid 
cell lineages: T cells (CD3, CD4 and CD8), B cells (CD19), and NK cells (CD56/16) 
from NiCord®, as shown in  Table  4.  
Two patients engrafted with a predominance of the unmanipulated CBU (Table 3) . These 
patients achieved neutrophil engraftment at 18 -26 days after transplantation, and platelet 
engraftment at 36 -49 days  (Table 2) . One patient failed to achieve engraftment 42 days 
after transplantation  (Table 2) , and received a  second stem cell transplant from a 
haploidentical donor .   
As of December 17, [ADDRESS_668165] experienced Grade 3 
hypertension events and one patient reported a Grade 3 hematuria on the day of 
transplantation . All three  events were resolved with no residual effects. Acute GvHD 
grade II was observed in five subjects (Table 2) .  
In addition to the eleven patients described above, o ne patient received only the 
unmanipulat ed CBU  due to a positive Gram stain result obtained from the  NiCord® CF 
during release  testing . NiCord® CF and NF were not infused to the patient and were 
discarded. NiCord® CF was tested for complete sterility (14 and 21 days) and the results 
of all the sterility tests were negative.  The patient achieved hematopoietic recovery 
following infusion of the unma nipulated unit and is alive at [ADDRESS_668166] three 
and six patients completed 100 days follow -up, with a subsequent recommendation to 
continue study accrual and transplantations .  
3.5.2.  Study GC P#02.01.020  
The study GC P#02.01.020  entitled: “Allogeneic Stem Cell Transplantation of NiCord®, 
Umbilical Cord Blood -derived Ex Vivo  Expanded Stem and Progenitor Cells , in 
Combination with a Second, Unmanipulated Cord Blood Unit in Patients with Sickle Cell 
Disease ” is ongoing at Duke University Medical Center, NC, [LOCATION_003]  and Cohen Children’s 
Medical Center of [LOCATION_001] . The study is evaluating the transplantation of NiCord® in 
combination with an unmanipulated CB U, for hematopoietic support of subjects with 
Sickle Cell Disease (SCD) . The study was launched in May 2012. The first patient was 
 
 
GC P# 03.01.020  Date: August [ADDRESS_668167]® Single CBU Protocol   Page [ADDRESS_668168]® in a double cord blood configuration.  
 
 
GC P# 03.01.020 .    Date: August [ADDRESS_668169]® Single CBU Protocol        Page 33 
 
 
Table  2:  Data from NiCord® Study ( GC P#01.01.020 ) - Patient Follow -up 
Patient 
Number  Disease 
Stage/ Age Myeloid Engrafted 
CBU  WBC at Day 
7 (/mm3) 
 Engraftment Day  Acute GvHD  
Grade (II -IV) 
 Last Study Follow Up 
Post Transplanta ANC 
>500  Platelet 
>20,000  
1 AML  (CR1) /[ADDRESS_668170]® + 
Unmanipulated CBU  200 14 33 aGvHD-II 
(Day 60)  376 
2 MDS (Int-2)/[ADDRESS_668171]® 300 11 30 No  aG vHD 372 
3 MDS (Int-2)/[ADDRESS_668172]® 500 10 30 No  aGvHD 348 
6 AML (CR2) /[ADDRESS_668173]® 400 10 30 No  aG vHD 393 
7 HL/[ADDRESS_668174]® 1100  7 26 aGvHD-II 
(Day 60)  355 
9 AML (CR1)/[ADDRESS_668175]® 100 14 41 aGvHD -II 
(Day 80)  196c 
10 AML (PR)/[ADDRESS_668176]® 500 18 - No  aGvHD  47d 
11 ALL (CR1)/[ADDRESS_668177]® 900 7 33 aGvHD-II 
(Day 60)  333 
4 AML (CR2) /41 Unmanipulated CBU  100 18 36 No  aG vHD 364 
5 AML (CR1) /57 Unmanipulated CBU  100 26 49 aGvHD-II 
(Day 35)  404 
8 NHL /[ADDRESS_668178] follow -up, as of 13 December , 2013  
b Total blood chimerism at day 7: NiCord® 95%, unmanipulated CBU 2%  
c Patient Died at [ADDRESS_668179] transplant  
 
 
 
GC P# 03.01.020 .    Date: August [ADDRESS_668180]® Single CBU Protocol        Page 34 
 
Table  3:  Data from NiCord® Study ( GC P#01.01.020 ) - Chimerism of NiCord® and Unmanipulated CBU  
Patient 
Number  Disease 
Stage/ Age Myeloid Engrafted CBU  Chimerism of NiCord® and Unmanipulated CBU  
Total Blood Chimerism at 
Engraftment Day  Last Follow -up Chimerism  
NiCord® 
(%) Unmanipulated  
CBU (%)  At 
Day NiCord® 
(%) Unmanipulated  
CBU (%)  
1 AML(CR1) /[ADDRESS_668181]® + Unmanipulated 
CBU  79 21 365 TBCa -  ND 
CD15 - 42  
CD3 - 2 TBC -  ND 
CD15 - 58 
CD3 – 78 
2 MDS (Int-2)/[ADDRESS_668182]® 100 0 365 TBC -  98 
CD15 - 98  
CD3 - 98 TBC -  2 
CD15 -2 
CD3 -2 
3 MDS (Int-2)/[ADDRESS_668183]® 95 5 365b TBC -  92 
CD15 - 98  
CD3 - 97 TBC -  2 
CD15 - 2 
CD3 – 2 
6 AML (CR2) /[ADDRESS_668184]® 98 1 365 TBC -  98 
CD15 - 98 
CD3 - 81 TBC -  2 
CD15 - 2 
CD3 – 2 
7 HL/[ADDRESS_668185]®  98 2 365 TBC -  84 
CD15 - 98 
CD3 - 24 TBC -  16 
CD15 - 2 
CD3 – 76 
9 AML (CR1)/[ADDRESS_668186]®  87 7 180 TBC -  ND 
CD15 - 72 
CD3 - 40 TBC -  ND 
CD15 - 2 
CD3 – 2 
10 AML (PR)/[ADDRESS_668187]® 100 0 42 TBC -  100 
CD15 - ND 
CD3 - ND TBC -  0 
CD15 - ND 
CD3 – ND 
11 ALL (CR1)/[ADDRESS_668188]® 98 2 365 TBC -  98 
CD15 - 98 
CD3 - 98 TBC -  1 
CD15 - 1 
CD3 – 2 
4 AML (CR2) /41 Unmanipulated CBU  2 98 365b TBC -  2 
CD15 - 2 
CD3 - 2 TBC -  98 
CD15 - 98 
CD3 – 98 
5 AML (CR1) /57 Unmanipulated CBU  2 98 365b TBC -  2 
CD15 – 2 
CD3 – 2 TBC -  98 
CD15 – 98 
CD3 – 98 
a Total Blood Chimerism   b TBC is day 365 , CD3/15 are day 180 .    
 
 
GC P# 03.01.020     Date : August [ADDRESS_668189]® Single CBU Protocol        Page 35 
____________________________________________________________________  
   
     
     
               
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
 
 
 
GC P# 03.01.020     Date : August [ADDRESS_668190]® Single CBU Protocol        Page 36 
 ______________________________________  
 
  
  
 
 
 
 
 
 
 
 
 
 
     
            
            
            
            
            
            
            
            
            
            
            
          
 
 
GC P# 03.01.020   Date : August [ADDRESS_668191]® Single CBU Protocol   Page [ADDRESS_668192]® is an allogeneic graft for HSCT composed of CB -derived stem and progenitor 
cells expanded ex  vivo from an entire CBU with cytokines and nicotinamide , as well as 
non-cultured CD133 - cells. NiCord is intended for the treatment of patients who are 
medically indicated for allogeneic hematopoietic stem cell transplantation following 
preparative  conditioning , including  high risk hematological malignancies . Non -clinical 
studies have demonstrated that culturing CD133+ cells with NAM delays differentiation 
and increases engraftment efficacy.  
UCB is an easily procured stem cell source for allogeneic HSCT, with high availability 
for patients of different ethnic backgrounds. H owever, its use is limited by [CONTACT_515640], compromising robust and timely hematopoietic recovery, leading to increased 
morbidity and mortality post transplantation. Several technologies are attempting to 
improve the kinetics of engraftment follo wing UCBT, by [CONTACT_515641], whereby [CONTACT_515642] -vivo manipulation or expansion. Such technologies may 
shorten the time to neutrophil engraftment, however the long -term durable hematopoietic 
recovery is provided by [CONTACT_33160], unmanipulat ed CBU.  
The first study of NiCord® (GC P#01.01.020 ) has demonstrated that infusion of NiCord® 
together with a second unmanipulated CBU was well tolerated. Engraftment of NiCord® 
cells in eight of eleven patients provided rapid short term neutrophil and pla telet recovery 
as well as stable, long term multilineage hematopoiesis. No NiCord® recipi[INVESTIGATOR_515612]. Five of the eleven who received the NiCord® 
study product developed grade II acute GvHD. Two patients died during the study period 
(AML relapse and pneumonia). Neither death was considered related to NiCord®. 
As in all cases of allogeneic HSCT, the overall risks of cord blood  administration 
following a cytotoxic preparative regimen can be serious and fatal. The potential risks 
associated with cord blood  include early death, infusion reactions, GvHD and graft 
failure.  The deaths and other adverse events experienced by [CONTACT_331236]® recipi[INVESTIGATOR_515613] P#01.01.[ADDRESS_668193]® to safely and durably engraft, 
when given as a sole stem cell source. Thus the primary endpoints assess t he safety of 
NiCord® infusion, NiCord®-derived neutrophil engraftment , and secondary graft failure. 
The secondary endpoints assess non -relapse mortality and overall survival up to one year 
post transplantation, as well as the time to engraftment, and the i ncidence of GvHD.  
3.7. Rationale For Study Design & Dosages  
3.7.1.  Study Population  
As reviewed above, the study will include adult and adolescent patients with 
hematological malignancies for whom myeloablative SCT is currently a recommended 
and potentially lifesaving  treatment . __________________  the study will _____  enroll 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668194]® Single CBU Protocol   Page [ADDRESS_668195] a n adequate  suitably matched and readily available stem cell  
donor.  
3.7.2.  CBU Cell Dose  
The CBU intended for expansion is required to contain a pre-cryopreserved  (post -
processing) , total CD34+ cell count  of at least 8x106, as well as a pre -cryopreserved 
(post -processing) total nucleated cell count  of at least  1.8x109, and a total nucleated cell 
dose of at least1.8x107 TNC/kg  body weight, a dose predicted to be  sufficient in size to 
provide robust and sustained engraftment, based on the current clinical experience with 
NiCord® (study GC P#01.01.020  - see Table  5). __                                                            _           
________________________________________________________________________
________________________________________________________________________
______________________________________________________     
______________________________________________________ __________________
____________________________________  
________________________________________________________________________
_________________________________  
As transplantation is considered a life saving intervention in the study population, the 
select ion of the optimal CBUs is at the Investigator's discretion.  
3.7.3.  Selection of CBUs  
Decisions on the selection of CBUs are never arbitrary, but rather are based on specific 
histocompatibility data, cell dose, availability, and in some cases the source of the CB U. 
However, there is no clear consensus or evidence -based algorithm as to the hierarchy of 
these factors. Thus, some physicians believe cell dose is of greatest importance, some 
examine CD34+ dose, and others prioritize HLA matching.  For this reason , the p rotocol  
does not specify prioritization rules when more than one eligible  CBU is identified.  
Also, with regards to the use of unit(s) that does not meet the local applicable regulations, 
note that all the patients included in the study may be considered of  “urgent medical 
need ” by [CONTACT_515643], and have a high  (>50%) likelihood of 
death without receiving a CBU transplantation. The usage of  ineligible unit(s) or units 
with unusual findings (e.g. "incomplete ”) will on ly be permitted when no comparable 
eligible CBU is found, and  when this is the best CBU found for this patient. The 
Investigator will document the  urgent medical need, the CBU search results and selection 
rationale in such cases.   
3.7.4.  Study Endpoints  
In order to assess the safety of administration of NiCord® as a single expanded UCB unit , 
the primary endpoints were chosen to be  the cumulative incidence of patients with 
NiCord®-derived neutrophil engraftment at [ADDRESS_668196]®. 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668197]® Single CBU Protocol   Page [ADDRESS_668198]® transplantation.  
 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668199]® Single CBU Protocol   Page 40 
4. STUDY OBJECTIVES, HYPOTHESIS & STUDY ENDPOINTS  
4.1. Objectives   
 
Primary Objective s 
• Assess  the cumulative incidence  of patients with  NiCord®-derived neutrophil 
engraftment at 42 days  following  transplantation .  
• Assess the incidence of secondary graft failure at [ADDRESS_668200]® 
Secondary Objectives  
• Time from infusion to neutrophil engraftment  
• Time from infusion to platelet engraftment  
• Incidence of platelet engraftment at 100 days   
• Proportion of non -relapse mortality at 100 days  
• Incidence of  acute GvHD g rade II -IV and III -IV at 100 days  
• Incidence of chronic GvHD (limited or extensive) at 180 days and 1 year  
• Incidence of secondary graft failure at [ADDRESS_668201]® 
• Overall survival at 180 days and 1 year  
• Safety and tolerability of  NiCord® transplantation  
Exploratory Objectives   
• Immune reconstitution at 70, [ADDRESS_668202]® following myeloablative conditioning in  patients with 
hematological malignancies  will provide sustained engraftment.  
4.2. Definition Of Study Endpoints  
 
4.2.1.  Neutrophil Engraftment  
Neutrophil engraftment  is defined as achieving an absolute neutrophil count (ANC) 
greater than or equal to 0.5 x 109/L on 3 consecutive measurements on different days with 
donor chimerism ( < 10% host cells by [CONTACT_515644]) by [CONTACT_4475] [ADDRESS_668203] on or prior to Day 42 will be 
considered primary graft failure, with the following exceptions:  
• Backup CBU transplantation within [ADDRESS_668204]® transplantatio n due to 
NiCord® bioassays outside of the specification limits will not be sufficient 
evidence of graft failure.    
 
 
GC P# 03.01.020   Date : August [ADDRESS_668205]® Single CBU Protocol   Page 41 
 
• Infusion of an additional stem cell product after documented neutrophil 
engraftment will be considered secondary graft failure, even if it occurs on or 
prior to Day 42.  
Secondary graft failure  consists of documented neutrophil engraftment, followed by 
[CONTACT_515635] (< 0.5 x 109/L for three or more consecutive laboratory values  on 
separate days) with marrow cellularity <5%, without subsequ ent improvement occurring 
either spontaneously or after growth factor treatment.   Infusion of an additional stem cell 
product after documented neutrophil engraftment will be considered secondary graft 
failure.   
4.2.2.  Platelet Engraftment  
Platelet engraftment i s defined as the first day of a minimum of 3 consecutive 
measurements on different days such that the patient has achieved a platelet count 
>20x109/L and >50x109/L with no platelet transfusions in the preceding 7  days (count 
day of engraftment as one of the preceding 7 days). The first day of the three 
measurements will be designated the day of platelet engraftment.  
4.2.3.  Non-Relapse Mortality  
Non-Relapse mortality is defined as any death not preceded by [CONTACT_128472].  
4.2.4.  Acute and Chronic GvHD  
Incidence of acute GvHD  grade II -IV and  III-IV will be assessed based on the Consensus 
Conference on Acute GvHD grading  (Appendix A)  on day 1 00.   Chronic GvHD will be 
assessed on day 180 and year 1 and classified as limited or extensive according  to 
Appendix A.  
4.2.5.  Immune Reconstit ution  
Immune reconstitution will be assessed on days 70, 100, 180, 365. The humoral system 
will be assessed based on levels of immunoglobul ins (IgG, IgA, IgM). Cellular immune 
recovery will be assessed based on lymphocyte subset analysis to quantify the nu mbers 
and proportions of different lymphocyte subpopulations  (CD3, CD4, CD8, CD19, 
CD16/56), as well as additional immunophenotypi[INVESTIGATOR_331197].  T -Cell 
Receptor Excision Circles (TREC) analysis will be performed on days 100, [ADDRESS_668206]® Transplantation  
The safety and tolerability of NiCord® transplantation will be evaluated by [CONTACT_47972], 
incidence and frequency of adverse experiences and an estimation of the relationship to 
NiCord®, as well as infections and l aboratory data follow -up, with special emphasis on 
safety of cell therapy, including the detection of infusion reactions, transmission of 
infections, new malignancies and autoimmune diseases.  
 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668207]® Single CBU Protocol   Page 42 
4.2.7.  Other Definitions  
[IP_ADDRESS].  Response Criteria for Acute Leukemia  
• Bone Marrow Myeloblasts < 5% by [CONTACT_306840];  
• No circulating leukemic myeloblasts;  
• Neutrophil count ≥ 1,000/µL;  
• Absence of previous cytogenetic or molecular abnormality identified prior to 
transplantation in the bone marrow aspi[INVESTIGATOR_337].  
[IP_ADDRESS].  Response Criteria  for CML  
• Bone Marrow Myeloblasts < 5% by [CONTACT_306840];  
• No circulating leukemic myeloblasts;  
[IP_ADDRESS].  Response Criteria for Lymphoma  
Response criteria for lymphoma are described in Table 6 below  
 
 
GC P# 03.01.020     Date : August [ADDRESS_668208]® Single CBU Protocol        Page 43 
 
Table 4:  Response Definitions for Lymphoma  
Table 2. Response Definitions for Clinical Trials  
Response  Definition  Nodal Masses  Spleen, Liver  Bone Marrow  
CR Disappearance of all evidence of 
disease  (a) FDG -avid or PET positive prior to 
therapy; mass of any size permitted if 
PET negative  
(b) Variably FDG -avid or PET negative; 
regression to normal size on CT  
  
Not palpable, nodules 
disappeared   
Infiltrate cleared on repeat biopsy: 
If indeterminate by [CONTACT_5293], 
immunohistochemistry should be 
negative  
PR Regression of measurable disease 
and no new sites  ≥50% decrease in SPD of up to [ADDRESS_668209] 
dominant masses; no increase in size of other 
nodes  
(a) FDG -avid or PET positive prior to 
therapy; one or more PET positive at 
previously involved site  
(b) Variably FDG -avid or PET negative; 
regression on CT  
 ≥50% decrease in 
SPD of nodules (for 
single nodule in 
greatest transverse 
diameter); no 
increase in s ize of 
liver or spleen   
Irrelevant if positive prior to 
therapy; cell type should be 
specified  
SD Failure to attain CR/PR or PD  (a) FDG -avid or PET positive prior to 
therapy; PET positive at prior sites of 
disease and no new sites on CT or 
PET  
(b) Variably FDG -avid or PET negative; 
no change in size of previous lesions 
on CT  
   
Relapse disease or PD  Any new lesion or increase by 
≥50% of previously involved sites 
from nadir  Appearance of a new lesion(s) > 1.5 cm in any 
axis, ≥50% increase in SPD of more than one 
node or ≥50% increase in longest diameter of a 
previously identified node > 1 cm in short axis  
Lesions PET positive if FDG -avid lymphoma 
or PET positive prior to ther apy 
  
>50% increase from 
nadir in the SPD of 
any previous lesions   
New or recurrent involvement  
Abbreviations:  CR, complete remission; FDG  [18F]fluorodeoxyglucose; PET, positr on emission tomography; CT, computed tomography; PR, partial remission; SPD, sum of the 
product of the diameters; SD, stable disease; PD, progressive disease.  
From Cheson, B.D. et al.  Revised response criteria for malignant lymphoma.  J Clin Oncol  5:579 -586, 2007.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668210]® Single CBU Protocol   Page 44 
[IP_ADDRESS]   Relapse and Residual Disease  
Relapse of malignancy  - testing for recurrent malignancy in the blood, marrow or other 
sites will be used to assess relapse after transplantation. For the purpose of this study, 
relapse is defined by [CONTACT_501810], ALL, CML, 
MDS consistent  with pre -transplant feature s or radiologic evidence (including the 
recurrence of fluoro -deoxyglucose [FDG] -avid lesions on PET scan) of progressive 
lymphoma.  When in doubt, the diagnosis of recurrent or progressive lymphoma should 
be documented by [CONTACT_515645] .  
Minimal residual disease  - minimal residual disease is defined by [CONTACT_207125], or fluorescent in situ hybridization (FISH), or 
Southern blot or Western blot, or polymerase chain reaction (PCR), or other techniques, 
in the absence of morphological or cytogenetic evidence of disease in blood or marrow.   
Since the frequency of testing for minimal residual disease is highly variable among 
centers, and the sensitivity is highly variable among laboratory techn iques, evidence of 
minimal residual disease alone will not be sufficient to meet the definition of relapse in 
the context of this trial.  However, minimal residual disease that progresses will be 
considered as relapse and the date of relapse will be the da te of detection of minimal 
residual disease that prompted an intervention by [CONTACT_1963].     
Acute Leukemia - Relapse will be defined as any of the following:  
• > 5% blasts in the marrow, not attributed to other causes (e.g., bone marrow 
regenera tion)  
• The appearance of new dysplastic changes within the bone marrow . 
• Reappearance of leukemic blasts in the peripheral blood.  
• Reappearance of previous cytogenetic or molecular marker of disease present prior 
to transplantation.  
• The development of extra medullary leukemia or leukemic cells in the cerebral 
spi[INVESTIGATOR_872].  
• Institution of any therapy to treat relapsed disease, including withdrawal of 
immunosuppressive therapy or DLI, will be considered evidence of relapse 
regardless of whether the criteria des cribed above are met.  
 
Chronic Myelogenous Leukemia (CML ) –  
Hematologic relapse will be diagnosed when:  
1. Immature hematopoietic cells are persistently documented in the peripheral 
blood; or,  
2. There is myeloid hyperplasia in the bone marrow in the presence of cytogenetic 
relapse.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668211]® Single CBU Protocol   Page 45 
Cytogenetic relapse will be diagnosed when:  
1. 50% of the metaphases exhibit the characteristic 9;[ADDRESS_668212] 
ten metaphases analyzed; or,  
2. At least one metaphase exhibits the 9;[ADDRESS_668213] one month apart, regardless of number of 
metaphases analyzed.  
MDS  - Relapse will be defined as any of the following:  
• Satisfying above criteria for evolution into acute leukemia; or,  
• Reappearance of pre -transplant morphologic abnormalities, detected in two 
consecutive bone marrow specimens taken at least one month apart; or,  
• Reappearance of pre -transplant cytogenetic abnormality in at least one 
metaphase on each of two separate consec utive examinations at least one 
month apart, regardless of the number of metaphases analyzed.  
• Institution of any therapy to treat relapsed disease, including withdrawal of 
immunosuppressive therapy or DLI, will be considered evidence of relapse 
regardless of whether the criteria described above are met.  
 
Lymphoma - Relapse will be diagnosed when one or more of the following criteria apply:  
• Appearance of any new lesion more than 1.[ADDRESS_668214] are mostly benign.  
Thus, a therapeutic decision should not be made solely on the basis of the PET 
without histologic confirmation.  
 
• At least a 50% increase from nadir in the sum of the product diameters (SPD) of 
any previously involved nodes, or i n a single involved node, or the size of other 
lesions (e.g., splenic or hepatic nodules).  To be considered progressive disease, a 
lymph node with a diameter of the short axis of less than 1.[ADDRESS_668215] increase by 
 50% and to a size of 1.5 x 1.5 cm or mor e than 1.5 cm in the long axis.  
 
Lesions should be PET positive if observed in a typi[INVESTIGATOR_20359] -avid lymphoma or 
the lesion was PET positive before therapy unless the lesion is too small to be 
detected with current PET systems (<.1.5 cm in its long axis by C T). 
 
• Institution of any therapy to treat persistent, progressive or relapsed disease, 
including withdrawal of immunosuppressive therapy or DLI, will be considered 
evidence of relapse/progression regardless of whether the criteria described above 
are met.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668216]® Single CBU Protocol   Page 46 
[IP_ADDRESS]  CML Stages  
 
Chronic phase is defined as:  
• Stable, not hematologic remission: blasts present in marrow and/or peripheral 
blood, but disease does not qualify as accelerated or blast phase  
• Hematological remission: no blast cells or precursor cells in the blood or marrow  
• Partial cytogenetic remission: Ph+ metaphases >0% but < 35%  
• Complete cytogenetic remission: absence of Ph+ metaphases  
 
Accelerated phase is defined as:  
• WBC difficult to control (> 50 x 109/L despi[INVESTIGATOR_116175])  
• Rapid doubling of WBC (< 5 days)  
• Anemia or thrombocytopenia unresponsive to standard treatment  
• Persistent thrombocytosis (> 1000 x 109/L) 
• Cytogenetic abnormalities in addition to Ph+  
• Increasing splenomegaly  
• Marrow fibrosis  
 
Blasts Crisis is defined as:  
• > 5% blasts in the marrow, not attributed to other causes (e .g., bone marrow 
regeneration)  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668217]® Single CBU Protocol   Page [ADDRESS_668218]® and who, in addition, me t all of the following criteria:  
• Did not receive any stem cells up to day [ADDRESS_668219]®  
• Did not die prior to day 21 
• Received myeloablative conditioning therapy as specified in the protocol  
• Did not seriously contravene the eligibility criteria specified in  Section  5.2 below  
• Did not receive a NiCord® transplant that was outside the final process quality 
control (FPQC) limits specified in section 8.[ADDRESS_668220] received a transplant of CB cells but did not meet all of the 
above criteria will enter the main statistical analysis (ITT) but will be considered non -
evaluable for the per protocol analysis. For completing the per protocol analysis such 
patient s can be replaced.  
Any patient  can be removed from the study at any time if in the judgment of the 
Investigator further treatment is not in the best interests of the patient . Patients may also 
withdraw themselves from the study at any time and for any reason.  
Patient s will be defined as screening failures when withdraw n from the study before 
receiving NiCord® or as early termination/discontinuation, if dropout occurs after 
transplantation of the NiCord®.  Screening failures can be replaced.  
For early termination/discontinuation patient s, termination visit should be com pleted. In 
case such patient s did not withdraw consent, study investigator will make all effort s to 
gather information on the clinical outcomes as assessed during the usual clinical 
management of their disease over the first 365 days following transplantat ion and to 
capture this information in the CRF.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668221]® Single CBU Protocol   Page [ADDRESS_668222] be 12-65 years of age  
2. Patients with one of the following hematologic malignancies:  
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
________________ ____________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
________________________________ ____________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
________________________________________________ ____________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____ ________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________ ________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________ ________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________ ________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
________ ____________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
________________________ ____________________________________
 
 
GC P# 03.01.020   Date : August [ADDRESS_668223]® Single CBU Protocol   Page 49 
____________________________________________________________
____________________________________________________________
____________________________________________________________
________________________________________ ____________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
________________________________________________________ ____
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________ ________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________ ________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________ ________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
________________ ____________________________________________
________________________________________________  
Exclusion Criteria  
1. __________________________________________________________________
__________________________________________________________________
____________ ______________________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
____ ______________________________________________________________
__________________________________________________________________
__________________________________________________________________
______________________________________________________________ ____
__________________________________________________________________
__________________________________________________________________
 
 
GC P# 03.01.020   Date : August [ADDRESS_668224]® Single CBU Protocol   Page 50 
__________________________________________________________________
______________________________________________________ ____________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
______________________________________________ ____________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
______________________________________ ____________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
______________________________ ____________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
______________________ ____________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
______________ ____________________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
______ ____________________________________________________________
__________________________________________________________________
__________________________________________________________________
________________________________________________________________ __
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
________________________________________________________ __________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
________________________________________________ __________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
________________________________________ __________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
________________________________ __________________________________
 
 
GC P# 03.01.020   Date : August [ADDRESS_668225]® Single CBU Protocol   Page 51 
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
________________________ __________________________________________
__________________________________________________________________
__________________________________________________________________
___________________________  
Graft Selection  
• If more than one unit meets the minimu m cell dose and HLA match requirements, 
the best available unit per investigator discretion should be selected for expansion.   
• CBUs should be procured from public banks that meet local applicable regulations. 
If the chosen unit for the patient is determine d ineligible or with unusual findings 
as per regulation, the unit may be used under the urgent medical need provision  
• The u nit selected for expansion  should be typed twice (i.e. initial typi[INVESTIGATOR_515614]). Confirmatory typi[INVESTIGATOR_331209] a la boratory  that is 
ASHI/EFI accredited and must come from an attached segment  
Backup Grafts  
• In case NiCord® fails to meet the required specifications , the backup CBU  will be 
transplanted  as detailed in section 8.3 . The clinical site will notify the CBB and 
the backup CBU will be shipped and transplanted.  
 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668226]® Single CBU Protocol   Page 52 
6. CONCOMITANT MEDICATIONS & SUPPORTIVE 
CARE  
6.1 Previous Medications  
All medications taken by/given to the patient , as a treatment for the primary and 
concomitant diseases within 30 days prior to screening, will be recorded in the patient 
files. 
All chemotherapy and radiotherapy courses administered to the patient, as prior treatment 
for his/her hematological malignan cy, will be recorded in the CRF (including treatment 
regimen, number of cycles, and dates).  Sites should obtain this information from the 
referring physician for source verification.  
6.[ADDRESS_668227] transplant:  
• Methotrexate (unless approved in advance by [CONTACT_2728])  
• Any cytokines except G -CSF or GM -CSF should not be used (including IL -2 or 
others, unless approved by [CONTACT_2728])  
• The use of Bactrim is discouraged on or after day -2 until the t ime of  engraftment as 
it may delay engraftment, and is reserved only for cases where it is assessed to be 
essential and superior to all alternative medications  
• Investigational agents, unless previously approved by [CONTACT_456]  
6.[ADDRESS_668228] commit to use the same conditioning regimen for all patients 
transplanted at their center.  In unique cases where the use of a different conditioning 
regimen is deemed to be in the patient’s best interest, approval from the study chairs must 
be obtained prior to use  of the different regimen . 
 
Table 7:  Conditioning Regimen s 
Regimen A:  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668229]® Single CBU Protocol   Page [ADDRESS_668230]® Fludarabine# 40 
mg/m2 IV       
 x  x  x  x  
Cyclophosphamide 
60mg/Kg# IV 
(optional*)       
   x  x  
Thiotepa 5mg/kg IV 
(optional*) x x    
       
#Adjusted ideal body weight for adult patients  
*Either Cyclophosphamide or Thiotepa (not both) may be added to the TBI/Flu preparative regimen at the 
discretion of the managing physician , with consideration given to  nature of the underlying malignancy  
(cytogenetics and/or minimal residual disease) , patient risk status (extent of prior therapi[INVESTIGATOR_13265]/or 
comorbidities), and , increased risk of graft failure in chemotherapy naïve patients . Cyclophosphamide or 
Thiotepa addition is recommended for patients with CML.  
 
Regimen B : 
      Study     
      Day -7 -6 -5 -4 -3 -2 -1 0 
Treatment   
Thiotepa# 5mg/kg IV  x x    
REST  REST  Infusion of 
NiCord® Busulfan# 3.2 mg/kg 
IV    x  x  x  
Fludarabine# 50 
mg/m2 IV over 1 hour    x x x  
#Adjusted ideal body weight for adult patients  
Regimen C*: 
               Study     
              Day -5 -4 -3 -2 -1 0 
Treatment   
Clofarabine 30mg/m2  
 x x x x 
REST  Infusion of 
NiCord® Fludarabine 10mg/m2  
 x x x x 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668231]® Single CBU Protocol   Page 54 
Busulfan: weight based 
dosing#$  x x x x 
*Clofarabine infused for 1 hour followed by [CONTACT_515646] 1 hour, followed by [CONTACT_515647] 3 hours.  
#Dosing according to Bartelink et al,50  
$Cumulative target AUC (Area Under the Curve) = 90mg*h/L. Bu levels after 1st dose will be measured at 
5min, 1h, 2h and 4h after end of Bu infusion  
 
6.3.1 Radiotherapy (Regimen A)  
Patients may be treated either in the AP/PA position and/or in the right and left lateral 
position. Compensators or blocks may be used to compensate for the th inner parts of the 
anatomy (head, neck, lower legs and feet).  
Total dose will be 1350 cGy in 8 or 9 fractions over 4 or 5 days. Two fractions on the 
same day will be given at a minimum of 6 hours apart from beam on to beam on.  
Risks and Toxicities :  
TBI can cause: nausea and vomiting, diarrhea, parotitis (rapid onset within 24 -48 hours, 
usually self -limited), generalized mild erythema, hyperpi[INVESTIGATOR_371], fever, mucositis and 
alopecia.   Late effects include: possible growth retardation, vertebral deformit ies, 
cataracts, probable increased risk of secondary malignant neoplasms, sterility, 
nephropathy, interstitial pneumonitis and veno -occlusive disease.  
6.3.2 Fludarabine  Administration  (Regimens A , B, and C ) 
Regimen A: Fludarabine 40 mg/m2/day will be administer ed as a 60 minute IV infusion 
on days -5 through -2.  
Regimen B: Fludarabine 50 mg/m2/day will be administered as a 60 minute IV infusion 
on days -5 through -3.  
Regimen C: Fludarabine 10 mg/m2/day will be administered as a 60 minute IV infusion 
on days -5 through -2. Fludarabine will be given after 1h infusion of Clofarabine.  
Fludarabine will be dosed as per adjusted ideal body weight (see below for 
cyclophosphamide).  Refer to Appendix E, ‘Drug Labels’, for risks and toxicities of 
Fludarabine administrati on.  
6.3.3 Cyclophosphamide (CY)  Administration  (Regimen A)  
Cyclophosphamide will be added to the preparative regimen at the discretion of the 
managing physician.   Reasons for the addition of cyclophosphamide include high -risk 
features of underlying malignancy ( cytogenetics and/or minimal residual disease) , patient  
risk status  (extent of prior therapi[INVESTIGATOR_13265]/or comorbidities) , and increased risk of graft 
failure in chemotherapy naïve patients .  Cyclophosphamide addition is recommended for 
patients with CML . 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668232]® Single CBU Protocol   Page 55 
Refer to Appendix E, ‘Drug Labels’, for risks and toxicities of c yclophosphamide 
administration.  
Cyclophosphamide 60 mg/Kg/day as per adjusted ideal body weight will be administered 
as per institutional practice.  
Doses and schedule for uroprotective agents  (i.e. M esna) should follow local institutional 
guidelines. For patients weighing more than 125% of their IBW, cyclophosphamide will 
be dosed based on the adjusted ideal body weight (AIBW).    
The following are dose adjustment formulas : 
▪ Ideal Body Weight ( IBW) formulas:  
- Males IBW = 50 kg+2.3 kg/inch over 5 feet  (or 50 kg + 0.91kg/cm over 
152.4cm)  
- Females IBW = 45.5 kg+2.3 kg/inch over 5 feet  (or 45.5 kg + 0.91kg/cm 
over 152.4cm)  
▪ Adjusted Ideal Body Weight (AIBW) formula:  
- AIBW = IBW+[(0.25)x (ABW -IBW)]  
6.3.4  Thiotepa Administration (Regimen A and B) 
Regimen A:  Thiotepa  5 mg/kg/day will be administered as a 4 hour IV infusion on days -
11 and -10. Thiotepa  will be dosed as per adjusted ideal body weight (as described in 
section 6.3.3  for cyclophosphamide).  
Regimen B: Thiotepa  5 mg/kg/day will be administered as a 4 hour IV infusion on days -
7 and -6. Thiotepa  will be dosed as per adjusted ideal body weight (as described in 
section 6.3.3  for cyclophosphamide).   
Refer to Appendix E, ‘Drug Labels’, for risks and toxicities of Thiotepa administration.  
6.3.5 Busulfan Administration (Regimen B  and C ) 
Regimen B: Busulfan  3.2 mg/kg/day will be administered as a 3 hour IV infusion (or in 
four separate 2 hour IV infusions every six hours ) on days -5 through  -3. Busulfan  will be 
dosed as per adjusted ideal body weight (as described in section 6.3.3  for 
cyclophosphamide).  Refer to Appendix E, ‘Drug Labels’, for risks and toxicities of 
Busulfan administration.  
Regimen C: Busulfan (weight -based dosing  according to Bartelink et al  50) will be 
administered over 3 hours IV infusion (or in four separate 2 hour IV infusions every six 
hours ) on days -5 through -3 (after clofarabine and fludarabine). Busulfan dose will be 
adjusted (if necessary) on the second day to achiev e a cumulative Busulfan ex posure 
(AUC) after 4 days of 90  mg*h/L  (+5 mg*h/L ). 
6.3.6 Clofarabine  Administration (Regimen C)  
Clofarabine 30mg/m2 will be administered as a [ADDRESS_668233], followed by 
 
 
[CONTACT_27199] P# 03.01.020   Date : August [ADDRESS_668234]® Single CBU Protocol   Page 56 
Fludarabine, in turn followed by [CONTACT_306676].   Refer to Appendix E, ‘Drug Labels’, for risks 
and toxicities of Clofarabine administration.  
6.4 GvHD Prophylaxis Medications  
All patients will receive GvHD prophylaxis with two drugs as  follows:  
 
Calcineurin inhibitor ( Tacrolimus  or Cyclosporine)  
Each transplant center  must commit to use the same calcineurin inhibitor (Tacrolimus or 
Cyclosporine)  for all patients transplanted at their center.  In unique cases where the use 
of a different calcineurin inhibitor is deemed to be in the patient’s best interest, approval 
from the study chairs must be obtained prior to use of the different calcineurin inh ibitor . 
Tacrolimus or Cyclosporine from day -3 through day +150 Target tacrolimus trough 
blood levels  of 5-15 ng/ml. If administering via continuous IV infusion, target 
cyclosporine trough levels of 200 -400 ng/mL by [CONTACT_331265] (or 100 -250 ng/mL by 
[CONTACT_515648] M S or equivalent level for other CSA testing methods) .  For intermittent dosing 
target cyclosporine trough levels of 150 -300 ng/mL by [CONTACT_331265] (or equivalent level 
for other CSA testing methods).  In the event of toxicity, dosing may be adjusted per 
institutional standard practice.  Calcineurin inhibitor  taper may begin at day +150 at the 
discretion of the managing physician , with the goal for discontinuation at day 180 -200.  
Refer to Appendix E, ‘Drug Labels’, for risks and toxicities of tacrolimus  admini stration.  
Mycophenolate Mofetil (MMF)  
Mycophenolate Mofetil (MMF) 1 g TID IV or PO (15 mg/kg IV TID if patient weighs 
<50 kg) beginning day -[ADDRESS_668235] day +[ADDRESS_668236] practice.  Refer to Appendix E, ‘Drug Labels’, for risks 
and toxicities of mycophenolate mofetil  administration.  
6.5 Acute & Chronic GvHD Treatment  
Management of acute and chronic GvHD will be at the Investigator's discretion and in 
accordance with the institution's guidelines.  
6.[ADDRESS_668237]  infusion.   
• Diphenhydramine 50 mg IVP  (or 0.5 mg /kg up to a maximum of 50 mg ) 
• Hydrocortisone 50 mg IVP (or 0.5 mg/kg  up to a maximum of 50 mg ) 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668238]® Single CBU Protocol   Page 57 
• Acetaminophen 650 mg PO (or 10 mg/kg  up to a maximum of 650 mg ) 
Methylprednisolone should not be used in conjunction with standard delivery of NiCord 
to the pati ent.  Management of infusion reactions during and post transplant is at the 
discretion of the managing physician.  
6.8 Supportive Cytokine Therapy  
G-CSF ( e.g. Filgrastim, Neupogen , Granix ) therapy will be started on day +1 at a dose of 
5 µg/kg/day (rounded to n earest vial size) given IV or SC and continuing at least until the 
ANC is >1,000/µl x 2 consecutive days as per site practice.  
6.9 Blood Products  
Thrombocytopenia: Platelet counts should be maintained at >10,000/uL after allogeneic 
transplant by [CONTACT_29470] o f platelets. When available, single donor platelets will be used.  
Anemia: Transfusions of packed red blood cells (RBC) are indicated for the management 
of symptomatic anemia  per institutional guidelines .  In the absence of symptoms, RBC 
transfusions should  be considered to maintain hemoglobin > 7g/dL.   
All blood products (except NiCord® or any other stem cell grafts administered)  must be 
irradiated to at least [ADDRESS_668239] frequently reported  
manifestations are transient fever, rash, and respi[INVESTIGATOR_515615]. The pathophysiology is poorly understood, but is thought to be 
multifactorial mediated by [CONTACT_2967], complement and cytokine components.  
Diagnostic cr iteria include fever (temperature >38.5° C) without an identifiable infectious 
cause prior to or with neutrophil recovery with or without an erythematous rash or 
capi[INVESTIGATOR_7946] (weight gain, edema, ascites, effusions) or respi[INVESTIGATOR_515616]. Mild symptoms may not require therapy due to the self -limiting 
nature of this syndrome. Methylprednisolone should not be given as prophylaxis  for 
engraftment syndrome prevention .  For progressive symptoms, methylprednisolone at 2 
mg/kg/day is re commended with tapering once response is achieved.  If recurrent or 
prolonged, investigation for GVHD is recommended.  
6.[ADDRESS_668240] 
guidelines fo r hygiene and care will be applied. Before starting the pre -transplant 
conditioning there should be no uncontrolled  mucosal or cutaneous infections.  Oral 
candida prevention should be vigorously pursued.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668241]® Single CBU Protocol   Page [ADDRESS_668242] be free of active 
infections. Rigorous hand washing is crucial.  
6.11.1  Anti-viral Prophylaxis  
Acyclovir 400 mg (or 250mg/m2) PO BID  is recommended for anti-viral prophylaxis 
with conditioning through the duration of neutropenia and then at 800 mg PO BID (or 
60–90 mg/kg /day PO divided in 2 –3 doses  for patients <40kg, up to a maximum of 
800mg BID ) until [ADDRESS_668243] be tested weekly for CMV using the PCR method after the start of the 
conditioning regimen  until Day 42±3 and then at day 70 ±5 and day 100 ±[ADDRESS_668244] be tested weekly after transplantation 
until absolute neutrophil count >500 cells/microliter.  Treatment is recommended if 
symptomatic or following 2 weeks of rising viral load or an absolute count above 10k  
copi[INVESTIGATOR_014] /ml.  Treatment for HHV6 should follow institutional practice.  If HHV6 
reactivation occurs at or before engraftment, treatment with foscarnet is recommended.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668245]® Single CBU Protocol   Page [ADDRESS_668246] monthly after the 
start of the conditioning regimen , or more frequently as clinically indicated, until day 100 
(or longer if on immunosuppression).  Patients with a positive result (>1000 copi[INVESTIGATOR_014]) 
should be treated as per institution al guidelines.  Rituximab treatment is recommended . 
6.11.8  Adenovirus Intervention Guideline  
Testing for adenovirus infection in the blood by [CONTACT_515649][INVESTIGATOR_331206], hepatic dysfunction or 
respi[INVESTIGATOR_23908]. If an active systemic infection is diagnosed, therapy should be 
instituted per institution al guidelines.  
6.11.9  Intravenous Immune Globulin  
Intravenous immune globulin may be administered according to institutional practice 
guidelines.  
6.11.10  Identif ication of Infectious Agents  - Recommendations  
[IP_ADDRESS]  Blood Cultures  
Blood cultures should  be taken at the presentation of fever  prior to  initiati ng antibiotics .  
In the event of clinical deterioration, suspi[INVESTIGATOR_515617] , or chills following 
initiation of broad -spectrum antibiotics, additional  cultures should  be taken.  Repeat 
cultures for subsequent epi[INVESTIGATOR_515618].  
[IP_ADDRESS]  Blood Culture Procedure  
Blood cultures should  be sampled twice per pr ocedure .  Each sample should  be tested for 
both aerobic and anaerobic organisms .  One sample should  come from the peripheral 
blood and one sample from the central line (or a second sample from the peripheral blood 
if the central line is no longer in use).    If a peripheral blood draw is not successful  and 
the patient has a central line with multiple lumens, then draw two  sample s from different 
lumen . 
[IP_ADDRESS]  Additional Identification Procedures  
The following procedures are recommended  in patients with suspected in fection:  
• Chest X -ray  
• Sinus CT in patients with suspected sinusitis  
• Diarrhea: Clostridium difficile toxin PCR to be determined once in patients with 
clinical suspi[INVESTIGATOR_2798]. Viral diagnostics (rotavirus, adenovirus, norovirus, astrovirus) 
in patients with clinical suspi[INVESTIGATOR_515619].  
• Urine culture in patients with s uspected infection of i ndwelling catheter   
• CSF culture in patients with suspected meningitis  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668247]® Single CBU Protocol   Page 60 
• Skin lesions: biopsy or aspi[INVESTIGATOR_337], for culture, Gram  stain , GMS and cytology.  
• Pulmonary source of infection: sputum culture in patients with productive cough. 
Cons ider viral diagnostics using viral throat swab, especially in sea son: Influenza 
A and B, RSV , Coronavirus, Rhinovirus, Bocavirus, Para -influenza, Human 
metapneumovirus and mycoplasm. BAL in patients with chest HRCT 
abnormalities.  
6.11.[ADDRESS_668248] 
from day 70 to the completion of follow -up. 
6.12 Nutrition  
All patients will be candidates for total parenteral nutrition; length of use is at the 
attending physician's discretion.   
6.[ADDRESS_668249] practices.  
6.14 Investigational Agents  
Unless approved by [CONTACT_1034], inve stigational agents should be withheld.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668250]® Single CBU Protocol   Page 61 
6.15 Other Medications  
Patient s should receive full supportive care according to institutions’ practice patterns 
and clinical guidance as described above, including transfusions of blood and platelets, 
antibiotics, anti -emetics, or any other supportive care according to clinical judgment.  
All concomitant medications and blood products administered, from time of signature [CONTACT_515666], will be recorded in the source documents  and the 
reason for administration should be clearly stated in the indications and if needed also 
documented as AEs.   All concomitant medications from time of transplant through ANC 
engraftmen t (or [ADDRESS_668251] transplant for non -engrafters) will be reported on the e -CRF.  
Rescue equipment (oxygen) and drugs such as hydrocortisone, epi[INVESTIGATOR_238] (other 
inotropic agents), and antihistamines should be available at the transplantation unit and 
will be administered at  the Investigator’s discretion.
 
 
GC P# 03.01.020     Date : August [ADDRESS_668252]® Single CBU Protocol        Page 62 
Table 8:  Evaluations & Examinations Flow Sheet  
     NiCord® Study for Single Fresh  - Schedule of Assessments Summary  
Baseline Days Post-transplant  
Phase  1: 
Screening  
Phase4 Phase  
2: 
Conditi
oning 
Phase1 Phase  3: 
Transplantation and FU Phase 
Days  -43 to      
-12/-10/ 
-8/-6 -11/-9/ 
-7/-5 
 to -1 0 1 2-
6 7 14±3 21±3 28±3 35±3 42±3 70
±3 100 
±14 180 
±21 365 
±21 
Identify UCB matching unit  for expansion and 
backup CBU /s 2 X               
Written Informed Consent3 X               
Eligibility Criteria4 X               
Confirm Eligibility within one week prior to 
conditioning  X               
CBU sent to  the production  site to arrive no later 
than two days before the start of manufacturing  X               
Medical History  X               
Infectious disease markers  5 X               
Anti-HLA antibodies  X               
Cardiac: EKG,  Echocardiography  or MUGA scan 
for LVEF [ADDRESS_668253], abdomen, pelvis  (HD/NHL)  8 X            X  X 
BM aspi[INVESTIGATOR_1516]/biopsy8  (when  clinically indicated) 
morphology   
In Leukemia/MDS: FACS; Cytogenetics; 
Molecular markers  X            X  X 
 
 
GC P# 03.01.020     Date : August [ADDRESS_668254]® Single CBU Protocol        Page 63 
 
  Days  
 -43 to      
-12/-10/ 
-8/-6 -11/-9/ 
-7/-5  
to -1 0 1 2-6 7 14±3 21±3 28±3 35±3 42±3 70±
3 100 
±14 180 
±21 365 
±21 
Vital Signs9 X10 X X X X X X X X X X X X X X 
Laboratory 11 X X X X X X X X X X X X X X X 
Historical and Concomitant 
medications13  X X X X X X X X X X X X X X X 
Karnofsky/Lansky performance 
scale  X        X   X X X X 
Physical Examination  X X       X   X X X X 
Complete urinalysis  X12               
Immunophenotypi[INVESTIGATOR_331207]14       X X X   X X X X X 
MultiPlex Immuno  Assays  
analyses14   X X  X X X   X     
Immunoglobulin s (IgG, IgA, 
IgM)  X           X X X X 
T-cell Receptor Excision Circles 
(TREC)  and  T cell receptor 
(TCR) beta within CD4+ & 
CD8+[ADDRESS_668255]® CF, NF, and infusion 
solutions shipped to transplant 
center prior to transplant   X              
NiCord® CF  thaw ing and  
infusion    X             
NiCord® NF thawing and infusion    X             
Toxicity  assessment [ADDRESS_668256] 
infusion17   X X            
 
 
GC P# 03.01.020     Date : August [ADDRESS_668257]® Single CBU Protocol        Page 64 
1   Start of conditioning varies by [CONTACT_515650]: Day -11/-[ADDRESS_668258]  include: CMV, Hepatitis panel (HepB sAg, HepB Core Ab, HepC Ab), herpes simplex virus, syphilis, HIV and HTLV I/II antibody, and varicella zoster.  
[ADDRESS_668259] ABO and Rh typi[INVESTIGATOR_276603].   
8 Baseline disease asse ssment should be as close  as possible to CBU shipment to the production facility  to minimize findings of relapse during CBU expansion.   Specific requirements for the 
timing of this assessment are provided in section 7.2.2  
9    Weight, t emperature, blood pressure, pulse, respi[INVESTIGATOR_515620].  
10  Including height, weight and BSA.  
11 CBC performed daily from Day 0 until neutrophil engraftment.  Differentials required if WBC >=0.[ADDRESS_668260] transplant  for non -engrafters .  Blood chemistries include  (at a minimum) : serum creatinine,  total bilirubin, alkaline phosphatase, AST, ALT, and 
magnesium (at screening, day -1, day [ADDRESS_668261] -transplant).  
12   As per site practice.  
13 Including total number of RBC and platelet units transfused until platele t recovery  >50k  
14  Samples batch -shipped  to University Medical Center Utrecht for analysis .  At screening and o n days 70, 100, 180, and 365 site will perform a basic  T-cell subset  analysi s (CD3, CD4, CD8, CD19, 
CD56/16) locally in addition to collecting  samples for batch shipment  to  University Medical Center Utrecht . 
15  Patient sample will be obtained prior to the initiation of the conditioning regimen; CBU sample will be shipped to the transplant center along with the NiCord product 
16 Measured by [CONTACT_331271], in whole blood and fractionated for lymphoid and myeloid components.  Bone mar row chimerism is an acceptable alternative.  
17 (fever, chills, allergic reaction/hypersensitivity, anaphylaxis, sinus bradycardia, sinus tachycardia, hypertension, hypotens ion, nausea, vomiting, diarrhea, dyspnea, hypoxia, 
hemoglobinuria,  infection, flank  pain and any other skin, CNS, cardiac, pulmonary or other toxicity manifestations)  
[ADDRESS_668262] - transplant.  
Days  
 -43 to      
-12/-10/ 
-8/-6 -11/-9/ 
-7/-5 
 to -1 0 1 2-
6 7 14±3 21±3 28±3 35±3 42±3 70±3 100 
±14 180 
±21 365 
±21 
Assess Acute GvHD 18      X X X X X X X X X X 
Assess Chronic GvHD              X X X 
CMV PCR   X    X X X X X X X X   
EBV PCR   X      X    X X   
HHV6 PCR weekly until 
ANC>[ADDRESS_668263] transplant until end of study  
Adverse events   From initiation of conditioning regimen until end of study  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668264]® Single CBU Protocol   Page 65 
7. DETAILED STUDY PLAN  
7.1. Pre-Screening Activities: Search For Matching CBUs  
 
Potential candidates for CBT for whom a search yielded a matched CBU  will be 
identified as screen candidates for the study. Patients must have one partially HLA -
matched CBU. The u nit must be HLA -matched at 4 -6/6 HLA class I (HLA -A & HLA -B, 
low resolution) and II (HLA -DRB1, high resolution) loci with the patient.   There mus t be 
at least one allele match at DRB1.  
 
________________________________________________________________________
________________________________________________________________________
_______________________________________________________________________ _
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
_______________________________________ __________________      
 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________ ________________________________________________________
________________________________________________________________________
________________________________________________________________________
_______________________________________________________  
 
All CBUs should be procured from public banks that meet local applicable regulations. 
Donors are screened and tested in accordance with  the relevant regulatory requirements . 
The CBU should be tested for the applicable infectious diseases and be eligible. In case 
the CBU is ineligible or with unusual findings, the clinical site should fill out an urgent 
medical need document.  
 
Once matching CBUs have been found, the patient  will be required to sign a written 
informed consent  for cord blood access as per Ins titutional and National requirements . 
 
If more than one unit meets the minimum cell dose and HLA match requirements, a ll 
CBU documents for expansion eligible units should be sent to the Sponsor's study 
logistics manager (SLM) for eligibility review .  At th e request of the investigator, the 
SLM will send the CBU documents to the study chairs for a recommendation on the best 
available unit.  Ultimately, the investigator chooses the best available units for expansion 
and backup from among all eligible units.      
 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668265]® Single CBU Protocol   Page [ADDRESS_668266]  be typed twice (i.e. initial typi[INVESTIGATOR_515621]). Confirmatory typi[INVESTIGATOR_331209] a lab that is ASHI/EFI accredited and must 
come from an attached segment.  
 
7.2. Screening Assessments: ( Three weeks prior to CBU shipment to the 
production facility )Acceptable CBUs (meeting CBU acceptance criteria as 
defined above) must be identified and available prior to patient’s screening.  
7.2.1.  Informed  Consent and Registration  
A conference will be held with the patient and family to discuss this study and alternative 
treatments available for the treatment of the underlying disease.  The conference will be 
conducted by [CONTACT_458] [INVESTIGATOR_515622].  
Standard of care workup for transplant may be done prior to patient consent.  Prior to 
performing any study activities/evaluations that are not part of the site’s routine clinical 
practices, the patient must be thoroughly informed about all aspects of the st udy, 
including scheduled study visits and activities, and must sign the written informed 
consent. Informed consent from the patient and/or his/her legal guardian will be obtained 
using a form approved by [CONTACT_515651] o f the 
institution enrolling the patient.  A signed copy of the written informed consent should be 
given to the patient and/or his/her legal guardian.  
Patients will be registered -_____________________________________ __________  
_____________________________ ___________________________________________
________________________________________________________________________
______________________________________________________________ . 
7.2.2.  Eligibility and Baseline Assessments  
Unless otherwise specified, e ligibility and baseline assessments  must  be scheduled within 
three weeks  prior to CBU shipment to the production facility . Test s performed during 
pre-screening period according to the Centers’ routine evaluation of candidates for stem 
cell transplantation need not be  repeated, provided they were performed recently enough, 
as detailed below .  
Patient ’s eligibility for the study will be assessed. The activities will be performed as 
detailed in Table 9 and will include:  
• Baseline evaluation:  
 Medical history including primary and concomitant disease s. Concomitant 
medications  will be recorded in the patien t’s medical record.  
 Patient s’ performance score by [CONTACT_175739] /Lansky  scale  
 Physical examination and vital signs (including height, weight and BSA ) 
 Laboratory: CBC  with WBC differential , blood chemistry  (serum creatinine, 
total bilirubin, alkaline phosphata se, AST, ALT, and magnesium at a minimum ), 
serum beta HCG (females) (tests from the last week pri or to screening are 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668267]® Single CBU Protocol   Page 67 
acceptable) ; urinalysis including microscopic examination Anti-HLA antibod y 
testing  
 Immunoglobulin levels (IgG, IgA, IgM)  
 Lymphocyte subsets : CD3, CD4, CD8, CD19, CD16/56 and additional 
immunophenotypi[INVESTIGATOR_331197]  
 Collect b lood sample s for T -cell Receptor Excision Circles (TREC)  and T cell 
receptor (TCR) beta within CD4+ & CD8+  for batch shipment to University 
Medical Center Utrecht  
 Chest  X-ray (tests from within 6 weeks  prior to screening are acceptable) .   
 Bone Marrow  morphology (aspi[INVESTIGATOR_1516]/biopsy, when  clinically indicated) .  To 
minimize findings of relapse during CBU expansion , bone marrow must be 
assessed within : 
▪ six weeks prior to CBU shipment to the production site  for MDS patients 
who have never shown >20% blasts (leukemic transformation) in prior 
bone marrow biopsies  and have <5% blasts in the most recent assessment , 
CML patients who have never experienced blast crisis , Lymphoma 
patients . 
▪ three weeks prior to CBU shipment to the production site for all other 
patients  
▪ For Leukemia or MDS: peripheral blood and BM morphology 
(aspi[INVESTIGATOR_1516]/biopsy ), FACS assay, cytogenetics and molecular markers  
▪ For NHL and HD: CT abdomen, pelvis & chest (tests from within 6 weeks  
prior to screening are acceptable)  
 Serologic infectious disease markers  for HIV 1 /2 Ab, HTLV I/II Ab, HBsAg, 
HBcAb, HCV Ab, HSV Ab, VZV Ab, Syphilis  (RPR) , and CMV Screen (IgG or 
Total)  
 Physiologic reserves assessment:  
− Pulmonary Function Tests including Carbon Monoxide Diffusing 
Capacity (DLCO), FEV1, FVC, and oxygen saturation  (tests from within 6 
weeks  prior to screening are acceptable) . 
− 12 lead ECG  (tests from within 6 weeks  prior to screening are acceptable)  
− Echocardiography or MUGA with left ventricular ejection fraction 
(LVEF) (tests from within 6 weeks  prior to screening are acceptable).  
• UCB match:  
 Patient and CBU ABO and Rh typi[INVESTIGATOR_007]  
 Patient HLA class I  (A, B, and C)  & II (DRB1) high resolution confirmatory 
typi[INVESTIGATOR_007] .  Note that although the matching requirement per protocol only requires 
low resolution A and B matching, high resolution , DNA -based  confirmato ry 
typi[INVESTIGATOR_331212] A, B, and C , as well as DRB1.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668268]® Single CBU Protocol   Page 68 
 If more than one unit meets the eligibility criteria, all CBU documents for 
expansion eligible units should be sent to the Sponsor's study logistics manager 
(SLM) for eligibility review .  At the request of the investigator, the SLM will send 
the CBU documents to the study chairs for a recommendation on the best available 
unit.   
 Peripheral blood baseline sample for chimerism laboratory  
All above  mentioned activities  must  be completed pri or to sending the CBU to the 
production  site for expansion . 
7.3. CBU  Shipment & Receipt at the Production Site and Clinical Site  
Once the Investigator has confirmed  that the patient meets ______ _____________ 
____________________________________________________ _ Patients will retain the 
same study ID that was assigned during screening.  T he Sponsor's study logistics 
manager (SLM) and the CBBs or NMDP will be notified  of the planned timeline for 
transplantation . Following confirmation of shipment timelines by [CONTACT_515652], t he 
CBB will send the selected CBU for NiCord® expansion  to the production site, to arrive 
no later than two days before the start of production . Qualified personnel at the 
production  site will ensure that this is the requested CBU to be manipulated for the 
patient  according to communication with the SLM and based on the CBU accompanying 
documentation  ______________________________   
7.4. Transplant Suitability  Confirmation: ( Prior to the start of 
conditioning ) 
Confirm that the patient is still suitable for  transplant  according to standard site practice.  
The site investigator , or designee,  must sign a statement within 24 hours prior to  the start 
of conditioning  indicating that the patient remains suitable  for transplant .  Patients no 
longer suitable  for transplant will be treated according to investigator’s discretion and 
will be considered screen failures for this protocol.   
Additional viral screening is sugge sted prior to administration of the conditioning 
regimen to confirm absence of infection.  At the investigator’s discretion, p atients with 
fever or suspected minor infection should  await resolution of symptoms before starting 
the conditioning regimen. If, as a result of delays in the transplant schedule, tests and 
evaluations are no longer within  the acceptable timeframe for transplant suitability, these 
tests must be repeated prior to the start of conditioning.   
7.5. Myeloablative Conditioning Day ( -11/-9/-7/-5) to (-1)  
The preparative & conditioning regimen will be administered  as detailed in section 6.3.  
GvHD prophylaxis will be administered as detailed in Sec tion 6.4.  Patient monitoring 
during the conditioning phase (including physical examination, vital signs, CBC and 
blood chemistry) will be evaluated.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668269]® Single CBU Protocol   Page 69 
7.6. Transplantation Day (Day 0)  
Safety Assessment  
Prior to the transplantation of NiCord®, the patient  will be evaluated by [CONTACT_515653]:  
• Physic al Examination including weight  
• CBC, blood chemistry  (serum creatinine, total bilirubin, alkaline phosphatase, AST, 
ALT and magnesium, at a minimum)  
• Vital Signs: temperature, blood pressure, pulse, and respi[INVESTIGATOR_697]  
7.6.1.  Preparation and Infusion of NiCord®   
[IP_ADDRESS].  ________________________________ ____________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
________________________________________________ ____________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____ ________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________ ________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________ ________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________ ________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
________ ____________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
________________________ ____________________________________
____________________________________________________________
 
 
GC P# 03.01.020   Date : August [ADDRESS_668270]® Single CBU Protocol   Page 70 
____________________________________________________________
____________________________________________________________
________________________________________ ____________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
________________________________________________________ ____
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________ ________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________ ________________________________
__________________________________   
[IP_ADDRESS].  ____________________________________________________________
____________________________________________________________
____________________________________________________________
________ ____________________________________________________
__________________   
________________________________________________________________________
________________________________________________________________________
________________________________________ ________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________ ________________________________________________________________
____________  
________________________________________________________________________
________________________________________________________________________
___________________________________ _____________________________________
__________________________________________  
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________             __________   
[IP_ADDRESS].  __________________   
________________________________________________________________________
________________________________________________________________________
 
 
GC P# 03.01.020   Date : August [ADDRESS_668271]® Single CBU Protocol   Page 71 
________________________________________________________________________
____ ____________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________________________ ____________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________ ____________________________________________________________
_____________  
 Evaluation and Treatment of IPQC/FPQC Safety Tests Failure  
The following safety test results may not be available a t the time the patient is 
transplanted:  
• Final results of day [ADDRESS_668272]  performed on the CF  
• Results of day [ADDRESS_668273] Transplantation Follow -Up (Day 0  to 1)  
Safety assessment including:  
• Vital Signs  
• Asses sment of acute  toxicity [ADDRESS_668274] transplant  
• AEs Reporting  
• Filgrastim will be administered beginning on  day +1  
• Blood sample s for MultiPlex Immuno  Assays  collected for batch -shipment  to 
University Medical Center Utrecht  (day 0)  
7.7 Scheduled Treatment Visits (As Detailed In Table 8) 
7.7.1.  Scheduled Visits on Day 1, 2, 3, 4, 5, 6  
The following assessments are mandatory:  
• AEs  and concomitant medications (including RBC and platelet transfusions) will be 
recorded  
• Vital Signs  
• CBC with WBC differential (differential not required if WBC<0.2), blood chemistry  
(serum creatinine, total bilirubin, alkaline phosphatase, A ST, ALT and magnesium, 
at a minimum)  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668275]® Single CBU Protocol   Page 72 
• GvHD prophylaxis  as specified in S ection 6.4 
• Infection prophylaxis as specified in S ection  6.11 
• Blood sample s for MultiPlex Immuno  Assays  collected for batch -shipment to 
University Medical Center Utrecht  (day 1) 
7.7.2.  Scheduled Visits on Day 7/ Days (±3) 14, 21, 28, 35, 42 , 70/ Day (± 14) 100/ Days 
(+21) 180, 365    
The following assessments are mandatory:  
• Information about AEs, hospi[INVESTIGATOR_602],  and concomitant medications  (including 
RBC and platelet transfusions) will be recorded  in the patient’s medical record  
• Vital Signs  
• Physical examinat ion (days 28, 70, 100, 180 , and 365 ) including routine cardiac and 
pulmonary monitoring  
• Karnofsky /Lansky  performance status score (days 28, 70, 100, 180 , and 365 ) 
• CBC  with WBC differential (differential not required if WBC<0.2 ), blood chemistry  
(serum creatinine, total bilirubin, alkaline phosphatase, AST, ALT and magnesium, 
at a minimum)  
• CMV PCR weekly until day 100  
• EBV PCR ( monthly, or more frequently as clinically indicated, until day 100 , or 
longer i f patient is on immunosuppression )   
• HHV6 DNA assessment by [CONTACT_515654] >500    
• Peripheral blood collection for donor/host chimerism (days 7, 14, 21, 28, 42, 70, 100, 
180, and 365 only). Bone marrow chimerism is an acceptable alternative  to 
peripheral blood .  Whole blood chimerism and lin eage specific (CD3 and either 
CD15  or CD33 ) chimerism must  be performed.  In cases where NiCord® was 
transplanted with an additional CBU, chimerism testing will also delineate the donor 
source (donor1/donor2/host)  
• Bone Marrow (aspi[INVESTIGATOR_337]/biopsy, when  clinically indicated) for morphology (all) and 
for FACS, molecular markers and cytogenetics (if abnormal findings present at 
diagnosis for leukemia/MDS patients) -days 100 and 365  or other as per Investigator's 
discretion   
• CT abdomen,  pelvis, chest ( lymphoma only) (day 100, 180, and 365 or other 
schedule as per Investigator's discretion)  
• Blood sample s for Immunophenotypi[INVESTIGATOR_515623]  (days 7, 14, 21, 42, 70, 100, 180, and 365 ).   
 
 
GC P# 03.01.020   Date : August [ADDRESS_668276]® Single CBU Protocol   Page 73 
o On days 70, 100, 180, and 365 site will assess T-cell subsets (CD3, 
CD4, CD8, CD19, CD56/16) locally as well as collecting  samples for 
batch shipment  to  University Medical Center Utrecht  
• Blood sample s for MultiPlex Immuno  Assays  analyses  sent to Universit y Medical 
Center Utrecht  (days 7, 14, 21, 42) 
• Immunoglobulin levels (IgG, IgA, IgM) (days  70, 100, 180, and 365 ) 
• Blood sample s for T-cell Receptor Excision Circles (TREC)  and T cell receptor 
(TCR) beta  within CD4+ & CD8+  for batch shipment to University Medical Center 
Utrecht (days 100, 180, and 365)   
• GvHD assessment:   
 Acute: At every visit post transplant , or more fre quently as clinically indicated , 
Acute GvHD will be assessed according to the Consensus Conference on Acut e 
GvHD grading  (Appendix A)  
 Chronic: day s 100,180, and [ADDRESS_668277] criteria (Appendix A ) and also classified as mild, moderate, or severe, 
according to the National Institute of Health consensus grading criteria51. 
• GvHD prophylaxis  as specified in Section 6.4 
• Infection prophylaxis as specified in S ection  6.11 
7.7.3.  Evaluation and Treatment of Graft Failure  
Evaluation of Graft Failure : should a patient  suffer primary or secondary graft failure, an 
attempt will be made to determine the cause of failure. Evalua tion will include:  
• Bone marrow aspi[INVESTIGATOR_1516]/biopsy for morphologic analysis as well as 
cytogenetics, chimerism studies, viral/bacterial cultures including PCR 
analysis for Herpes  viruses (including CMV and HHV6) .  Assessment should 
be performed between day 2 1 and 42 for primary graft failure.  
Treatment of Graft Failure : If the patient has less than 100 PMN at day +[ADDRESS_668278] 
recent BM shows decreased marrow cellularity and paucity of donor cells (less than 20%) 
by [CONTACT_515655], this may be considered impending primary graft failure (different 
from actual graft failure as defined in section 4. 2.1). In a case of impending or actual 
graft failure, the patient will be treated at the discretion of the treating physician.  
Graft Rejection : Graft rejection will be defined by [CONTACT_515656] 42.  
In patients experiencing delayed or failed engraftment, serologic assessment of HHV6  
and CMV will be performed.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668279]® Single CBU Protocol   Page [ADDRESS_668280]® infusion.  
Patients who do not receive a NiCord® infusion  but are given a backup CBU are part of 
the intent to treat analysis and should be followed for ANC engraftment, secondary graft 
failure, survival, and relapse .  
For early termination patients that withdr aw/are withdrawn from the study post 
transplant, any assessments due at the time of withdrawal  (according to Table 9) are 
requested.  
Patients who experience graft failure or relapse post transplant will continue to be 
followed for survival.  No other study related assessments are required for  these subjects 
after the date of graft failure or relapse.  
 
7.7.5.  Criteria for Early Termination/Discontinuation  
Patient s who are prematurely discontinued from the study should be followed and treated 
by [CONTACT_166842] . Patient s who join the study will 
be asked for permission that their clinical investigator be allowed to transmit information 
to the trial center on the clinical outcomes as assessed during the usual clinical 
management of their disease over the first 365 days following treatment. This will allow 
us to continue to gather clinical information on patient s who subsequently withdraw from 
active participation and did not withdraw informed consent, and to include them in the 
analyses of all clinical endpoints.  
A patient  may withdraw or be withdrawn from the study for the following reasons:  
• Patient withdrew consent  
• Sponsor requested patient  to be withdrawn  
• Request of primary  care physician or Investigator  
• Non-compliance (per investigator judgment)  
• Lost to follow -up 
• AE 
7.8. Data Reporting  
7.8.1.  Criteria for Forms Submission  
Criteria for timeliness of submission for all study forms are detailed in the Data 
Management Handbook and User’s Guide. ______________________________  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668281]® Single CBU Protocol   Page 75 
________________________________________________________________________  
_______________________________ _________________________________________  
________________________________________________________________________  
________________________________________________________________________  
____________________________________________________________________ ____  
Adverse Events will be reported as outlined in Section 9 of this protocol.
 
 
GC P# 03.01.020   Date : August [ADDRESS_668282]® Single CBU Protocol   Page [ADDRESS_668283]® 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________ ________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________ ________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________ ________________________
____  
8.2. CBU Supply  
All CBUs should be procured from public banks that meet local applicable regulations.  If 
the optimal unit(s) for the patient was determined ineligible or with unusual findings as 
per local regulations, the unit may be used under the urgent medical need provision and 
in consultation with the sponsor.  
NiCord® CF and NF manufacturing  will be performed by [CONTACT_1034]'s  central 
production  site in Israel.  
Myeloablative , GvHD prophylaxis, immunotherapy support and other supportive care, as 
detailed in Section 6, will be supplied by [CONTACT_3452].  
8.3. Manufacturing  
NiCord® is manufactured in a production  site, inside a laminar flow hood (class 100, ISO 
5) within a room tha t has been qualified as a Class 10,000 (ISO 7), in compliance with 
the production instructions and procedures as provided by [CONTACT_1034].  
Quality control (QC) tests are performed throughout the course of the manufacturing and 
on the final product and their  results are documented. The testing includes in -process 
quality controls (IPQC) and final process quality controls (FPQC) performed according 
to ___________________ . The IPQC and FPQC tests are performed according to written  
analytical methods either by Q C employees or by [CONTACT_515657].  
IPQC samples from NiCord® are taken at different identified stages during the process 
and include both Bioassays and Safety tests as detailed in the table  below . 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668284]® Single CBU Protocol   Page 77 
Table 9: 
________________________________ ____________________________
____________________________________________________________      
 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________ ________________________________
________________________________________________________________________
_______________________  
 
 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668285]® Single CBU Protocol   Page 78 
Table 10:-----------------------                        
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
________________________________________________________________________
_______________________________________________________________________
_______________________________________________________________ 
 
  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668286]® Single CBU Protocol   Page 79 
Table 11:  
____________________________________________________________
____________________________________________________________
____________________________________________________________
__________________________   
     
     
     
     
     
     
     
     
______________________________________________________________________________________
____________________________________________________________________________________
____________________________________   
 
All the safety and some  of the IPQC and FPQC bioassays tests have specifications and 
the results should be within the provided specifications. Some of the IPQC and FPQC 
bioassays do not have specifications and results are only collected and documented.  
__________________________ _____________________________________________  
________________________________________________________________________
______________________________________________________________________  
___________________________________________________________________ ___ 
 
8.3.1.  Safety OOS Results  
In the event that a safety test result failed to meet its specification, an immediate 
investigation is initiated. The resulting report will be attached to the deviation report and 
filed in the Batch Record.  
• _________________________ _________________________________________  
__________________________________________________________________  
• ____________________________________________________________________
____________________________________________________________________
__________  
• ____________________________________________________________________
____________________________________________________________________
____________________________________________________________________  
• ___________________________________________________ _________________
____________________________________________________________________
____________________________________________________________________
___________________________________   
 
 
GC P# 03.01.020   Date : August [ADDRESS_668287]® Single CBU Protocol   Page 80 
i. _______________________________  
ii. __________________________________ ________________________________
___________  
iii. __________________________________________________________________
_______________________________________________  
8.3.2.  _______________________________________  
________________________________________________________________________
________________________________________________________  
• ____________________________________________________________________
___________________________________________________________ _________
__________________________________________________________________   
• ____________________________________________________________________
____________________________________________________________________
___________________________________________ _________________________
__________________________________________________________________  
• ____________________________________________________________________
____________________________________________________________________
____________________________ ________________________________________
___________________________________  
________________________________________________________________________
__________________________________________________                                    
_______________________ _________________________________________________
________                                                                                                 ____  
In the case of European clinical site, the product is shipped with a QP "release for 
shipment" certificate and the different CoAs are faxed/emailed to the clinical sites with 
the QP "release for infusion" certificate.  
8.4. Handling of NiCord ®  
________________________________________________________________________
______________________________ __________________________________________
________________________________________________________________________
Shipment  
NiCord® __________________________________________  will be shipped under 
quarantine status with all available CBU segments to the  clinical site in a cryoshipper  
equipped with a calibrated data logger  prior to transplantation  with all necessary 
documentations.  
________________________________________________________________________   
The shipment of NiCord® will be controlled by [CONTACT_515658]. The 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668288]® Single CBU Protocol   Page 81 
checks performed will be documented in a special form ___________________________  
When a shipment is received, the Investigator/Coordinator will a cknowledge receipt.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668289]® Single CBU Protocol   Page 82 
9. SAFETY MONITORING  
9.1. Definitions  
9.1.1.  Adverse Event (AE)  
Adverse event means any untoward medical occurrence associated with the use of the 
investigational product , whether or not considered related  to the investigational product .  
Treatment -emergent AEs are any  AEs that occur or worsen (i.e. increase in grade) during 
or after the infusion of the study product . 
9.1.2.  Infusion Reaction  
Any adverse event that occurs or worsens (i.e. increases in grade) betwe en the start of the 
cord blood  infusion and [ADDRESS_668290] blood  infusion.   
9.1.3.  Serious Adverse Event (SAE)  
An adverse event or suspected adverse reaction (see section 9.1.4) is considered “serious” 
if, in the view of either the investigator or sponsor, it fulfils one or more of the following 
criteria :  
• Results in d eath  
• Is life-threatening  
NOTE: An event is considered "life -threatening" if, in the view of either the 
investiga tor or sponsor, its occurrence places the patient or subject at immediate 
risk of death. It does not include an adverse event or suspected adverse reaction 
that, had it occurred in a more severe form, might have caused death.   CTCAE 
grade four events are n ot automatically defined as life threatening for SAE 
determination.  For example, a grade four increase in ALT/SGPT may or may not 
be deemed as life threatening by [CONTACT_1755]/or sponsor.  
• Requires inpatient hospi[INVESTIGATOR_515624]:  Complications that occur during hospi[INVESTIGATOR_1084].  If a 
complication prolongs hospi[INVESTIGATOR_9236], the 
event is serious.  Elective or previously scheduled hospi[INVESTIGATOR_31643] -existin g 
conditions which have not worsened after initiation of treatment should not be 
classified as SAEs.  Any hospi[INVESTIGATOR_515625] .  
• Results in  persistent or significant disability or incapacity  
NOTE:  The term disability is defined as a substantial disruption of the ability to 
conduct normal life functions .   This definition is not intended to include 
experiences of relatively minor medical significance, such as uncomplicated 
headache, nausea, vomiting, diarrhea, influenza, or accidental trauma (i.e., 
sprained ankle) that may interfere or prevent everyday life functions but do not 
constitute a s ubstantial disruption.   
• Is a congenital anomaly/birth defect.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668291]® Single CBU Protocol   Page [ADDRESS_668292]  caused  the event.  “Reasonable possibility” 
means there is evidence to suggest a causal relationship between the study product  and 
adverse event.  
The Investigator must make the determination of relationship to the study product for 
each AE/SAE.  Alternative caus es, such as natural history of the underlying diseases, 
concomitant therapy, other risk factors, and the temporal relationship of the event to the 
study product, will be considered and investigated. The Investigator will also consult the 
Clinical Investiga tor’s Brochure and/or Product Information for marketed products in the 
determination of his/her assessment.  
9.1.5.  Causality  
The Investigator will use the following question  when assessing causality of an adverse 
event to study product :  Is there a reasonable possibility that the study product  caused 
the event?   An affirmative answer designates the event as a suspected adverse reaction.   
9.1.6.  Expectation  
Unexpected: An event is considered “unexpected” when it is not listed in the IB or it is 
not listed at the specificity and severity that has been observed. It  also refers to adverse 
events or suspected adverse reactions that are mentioned in the investigator ’s brochure 
but are not specifically mentioned as occurring with the particular study p roduct  under 
investigation.  
9.1.7.  Toxicity Grading  
GvHD symptoms will be graded according to the Consensus Conference on Acute GvHD 
grading52 for acute GvHD and National Institute of Health consensus grading criteria51 
for chronic GvHD.  
Infections will be graded according to the infection grading scale provided in the Data 
Management Handbook.  
All other AEs will be graded using NCI’s Common Terminology Criteria for Adverse 
Events (CTCAE ) Version 4. 03.   
An AE that is assessed as CTCAE grade three (i.e. “severe”)  should not be confused with 
an SAE.  Severity is a category used for rating the intensity of an event; both AEs and 
SAEs can be assessed as severe.  An event is described as ‘serious’ when it fulfils one or 
more of the criteria  described in Section  9.1.3  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668293]® Single CBU Protocol   Page 84 
9.1.8.  Expedited Reporting  
The following events meet the criteria for expedited reporting and require submission of 
an Adverse Event Form  _______________  within 24 hours of knowledge of the event  
(note th at all SAEs require reporting within 24 hours of knowledge of the event, although 
not all SAEs will require expedited reporting to regulatory authorities) .  
• Grade 3-5 infusion reactions  
• Non-engraftment at [ADDRESS_668294]® infusion    
• All serious, unexp ected, suspected adverse reactions  as defined in 21 CFR312.32 and 
Directive 2001/20/EC  
A detailed summary of the events above are required from the Investigator within 2 
working days of knowledge of the event.  The summary will include date of onset, peak 
grade, potential causes, resolution date (if applicable), past medical history, concomitant 
medications, an event narrative, and actions taken.  A discharge summary or hospi[INVESTIGATOR_515626].    
Other Adverse Events that do not meet the criteria for expedited reporting should be 
recorded in the database as outlined in  Appendix B .  Clinical centers are expected to 
report AEs to their IRB /EC according to their own institutional guidelines.  
An expedited report will also be submitted if an aggregate analysis indicates that serious 
expected serious adverse reactions are occurring more frequently or at a higher severity 
than what was previously expected.  
9.2. Observation, Detection and Recording of A Es and SAEs  
The Investigator and/or study personnel will enquire about the occurrence of AEs at 
every visit, after the subject has had the opportunity to spontaneously mention any 
problems.   Because of their underlying disease and toxic preparative therapy , a wide 
range of adverse events are anticipated.   
All AEs will be recorded in the source documents with sufficient detail to allow for 
grading per CTCAE v4.03, and reported on the appropriate CRF page.  
▪ All infections post transplant will be reported on an infection form.   
▪ Graft versus Host Disease ( GvHD ) will be reported on GvHD forms.  
▪ __________________________________________________________________
__________________________________________________________________
_____________________________________ _____________________________
________________________________________________________________    
▪ __________________________________________________________________
________________________________________________  
▪ Serious Adverse Events post transplant will b e reported on SAE summary forms  
 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668295]® Single CBU Protocol   Page [ADDRESS_668296] transplant will be reported o n SAE summary forms.  These 
events  may require reporting on other forms as well (e.g. Death form when applicable), 
however they should not be reported on the Adverse Event Log form .  SAEs should be 
reported within 24hrs of the sites’ knowledge of the event . 
Where possible, a diagnosis rather than a list of symptoms should be recorded. The 
Investigator  will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. In such cases, the diagnosis should be documen ted as 
the AE/SAE and not the individual signs/symptoms.  If a diagnosis has not been made 
then each symptom should be listed individually.  
For every SAE that occurs between the time of patient consent and the participant ’s final 
study visit , the Investigat or is responsible for reviewing all documentation (e.g., hospi[INVESTIGATOR_41100], laboratory test results, and diagnostic reports) relating to the event.  For 
events that occur after the start of conditioning, t he Investigator or designee will then 
record all relevant information about an SAE onto the appropriate page of the CRF.  The 
Investigator must review, sign, and date an SAE  summary  report form to confirm the 
accuracy of the recorded information.  The signed report will be maintained in the site’s 
study files.  It is not acceptable for the Investigator to send photocopi[INVESTIGATOR_9238]’s 
medical records in lieu of completion of the appropriate CRF pages.  Unless otherwise 
requested, transfer of subjects’ medi cal records with the CRF should be restricted to 
hospi[INVESTIGATOR_515627], laboratory and radiology reports, discharge 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668297]® Single CBU Protocol   Page [ADDRESS_668298] 
identifiers (i.e., name, medical rec ord number) must be obliterated prior to faxing the 
documents to the designated project contact.  
9.3. Follow -up of AEs and SAEs  
All reported AEs and SAEs will be followed  and recorded  until resolution with or 
without sequelae  (the patient’s health has returned to baseline status or all variables have 
returned to normal),  until the condition stabilizes  (the Investigator does not expect any 
further improvement or worsening of the event) , until an outcome is reached or the event 
is otherwise explained,  or until the re is agreement between the Investigator and sponsor 
that additional follow -up is not warranted. The Investigator will ensure that follow -up 
includes any supplemental investigations as may be indicated to elucidate the nature 
and/or causality of the AE/SAE .  This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health care 
professionals.  Where appropriate, medical tests and examinations will be performed to 
document resolution of the event (s).  Additional follow -up information, if required, or 
available, must be reported in the same timelines as initial information .  New or updated 
information will be recorded on the originally completed CRF, with all changes to SAEs 
signed and dated by [CONTACT_515659]’s study files . 
9.4. Medical Monitor Review  
Both the  ________  Medical Monitor (MM) and the sponsor will be alerted  ___________ 
________________________________________________________________________
____  
• Grade 3 -5 infusion reactions  
• Non-engraftment at [ADDRESS_668299]® infusion    
• All serious adverse events   
The MM is responsible for initial review of these events within [ADDRESS_668300] informatio n is due within 2 
calendar days of the sites ’ knowledge of the event.   
9.5. Clinical Laboratory Evaluations  
All laboratory measurements will be evaluated for abnormalities.  An abnormal 
laboratory value should be primarily interpreted in the context of the dis ease or the 
condition leading to it. The latter (instead of the laboratory abnormality itself) should be 
reported as adverse event and graded, whenever possible. A laboratory adverse event i.e., 
a laboratory abnormality not associated with any particular c linical findings (e.g., 
symptoms, signs), will be reported when judged clinically significant by [CONTACT_093].  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668301]® Single CBU Protocol   Page [ADDRESS_668302]® to be 
considered clinically significant.   If a laboratory adverse event is reported, it will be 
graded using the CTCAE toxicity grading scale ve rsion 4.[ADDRESS_668303] notify the Sponsor of the outcome within 24 hours of the Investigator’s knowledge 
of the pregnancy outcome.  This notification includes pregnancies resulting in live, 
“normal” births.  
If the pregnant s ubject experiences an SAE during pregnancy, or the outcome of the 
pregnancy meets the criteria for classification as an SAE, the Investigator should follow 
the procedures for reporting SAEs (i.e., report the event to the Sponsor within 24 hours of 
the Inve stigator’s knowledge of the event).  
All neonatal deaths and congenital anomalies that occur within 30 days of birth 
(regardless of causality) should be reported as SAEs to the Sponsor.  In addition, any 
infant death or congenital anomaly occurring after [ADDRESS_668304] interests of the patient . Patients may also 
withdraw themselves from the study at any time and for any reason.   
9.8. Sponsor Obligations  
Any concerns regarding the type or frequency of an event  will be communicated to the 
DMC Chair by [CONTACT_456].  The DMC Chair will review the adverse event materials, 
determine if the information is complete, determine if additional DMC review is required 
and make recommendations to the sponsor concerning conti nuation or modification of 
the study.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668305]® Single CBU Protocol   Page 88 
9.9. Regulatory Authorities  and IRB/ECs  
The Sponsor shall notify the concerned Regulatory Authorities of Suspected Unexpected 
Serious Adverse Reactions (S[LOCATION_003]Rs) for the IMP, or other AEs as per local 
requirements. In accord ance with Directive 2001/20/EC and Chapter II of Volume 10 of 
the Rules Governing Medicinal Products in the European Community, the Sponsor will 
also report S[LOCATION_003]Rs to the EudraVigilance Clinical Trial Module (EVCTM).  
The Sponsor is responsible for reporti ng all unexpected fatal or life -threatening suspected 
adverse reactions to regulatory  authorities , as per the concerned authorities’ requirements  
no later than seven calendar days after knowledge of the event.  All grade [ADDRESS_668306]® infusion , and all other serious, 
unexpected, suspected adverse reactions  are reported to the regulatory  authorities by [CONTACT_152245] 15 calendar days of receipt of the information.   
The Sponsor or designee shall notify the Central Ethics Committees (CEC) of S[LOCATION_003]Rs 
or significant risks to subjects, per country requirements.  
The Sponsor or designee shall notify the Investigator of potential serious risks from 
clinical trials or any other sources, including the follo wing:  
• Suspected adverse reaction that is both serious and unexpected.  
• Any findings from other studies that suggest a significant risk in humans exposed 
to the drug.  
• Any finding from animal or in vitro testing that suggest a significant risk to 
humans  exposed to the drug, such as mutagenicity, teratogenicity, or carcinogenicity; or 
report of significant organ toxicity at or near the expected human exposure.  
It is the responsibility of the Principal Investigator (PI) to notify the IRB/EC of all SAEs 
that occur at his or her site. Each site is responsible for notifying their IRB/EC of these 
additional SAEs. The Investigator must keep copi[INVESTIGATOR_56594], including 
correspondence with the Sponsor or Local Ethics Committees on file.  
 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668307]® Single CBU Protocol   Page 89 
10. STATISTICAL ME THODOLOGY  
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________ ________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________ ________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________ ________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________ ________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________ ________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________ ________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________ ________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________ ________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________ ________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________ ________________________________________________________________
________________________________________________________________________
________________________________________________________________________
Patients & Analysis Cohorts  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668308]® Single CBU Protocol   Page 90 
10.4. Statistical Analysi s  
Primary Objectives  
• Assess  the cumulative incidence  of patients with  NiCord®-derived neutrophil 
engraftment at 42 days  following  transplantation .  
• Assess the incidence of secondary graft failure at [ADDRESS_668309]® 
Secondary Objectives  
• Time from infusion to neutrophil engraftment  
• Time from infusion to platelet engraftment  
• Incidence of platelet engraftment at 100 days  
• Proportion of non -relapse mortality at 100 days  
• Incidence of acute GvHD grade II -IV and III -IV at 100 days  
• Incidence of chronic GvHD (limited or extensive) at 180 days  and 1 year  
• Incidence of secondary graft failure at [ADDRESS_668310]® 
• Overall survival at 180 days and 1 year  
Exploratory Objectives  
• Immune reconstitution at 70, 100, 180, a nd 365 days  
10.4.1.  Primary Endpoints  
[IP_ADDRESS].  Neutrophil Engraftment  
To assess the incidence of neutrophil engraftment post transplant a cumulative incidence 
curve will be computed along with a 95% confidence interval at [ADDRESS_668311] -transplant.  
Death prior to engraftment will be considered as a competing risk.  
[IP_ADDRESS].  Incidence of Secondary Graft Failure    
The cumulative incidence of secondary graft failure out of those who had initial 
engraftment will be described using the cumulative incidence estimator, treating death 
and disease relapse/progression prior to seconda ry graft failure as a competing event.  
10.4.2.  Secondary Endpoints  
[IP_ADDRESS].  Time from Infusion to Neutrophil Engraftment  
The incidence of initial neutrophil engraftment will be estimated with a cumulative 
incidence curve with death as a competing risk.  Median time to n eutrophil (> 0.5x109/L) 
engraftment will be estimated among those in whom engraftment is achieved.    
 
 
GC P# 03.01.020   Date : August [ADDRESS_668312]® Single CBU Protocol   Page 91 
[IP_ADDRESS].  Time from Infusion to Platelet Engraftment  
The incidence of platelet engraftment ( >20x109/L and >50 x109/L) will be estimated with 
a cumulative incidence curve with death as a competing risk.  Median time to platelet 
(>20x109/L and >50 x109/L) engraftment will be estimated among those in whom 
engraftment is achieved.  
[IP_ADDRESS] Incidence of Platelet Engraftment at 100 d ays   
The incidence of platelet engraftment ( >20x109/L and >50 x109/L) will be estimated with 
a cumulative incidence curve with death as a competing risk.   
[IP_ADDRESS].  Non-Relapse Mortality  
To assess the incidence of non-relapse  mortality , a cumulative incidence cur ve of death 
occurring in a subject not preceded by  [CONTACT_515660] a 95% 
confidence interval at [ADDRESS_668313] -transplant.   Relapse  and progressive disease will be 
considered as a competing risk.  
[IP_ADDRESS].  Acute GvHD Grade II -IV and III -IV 
The cumulative incidence of patients who experience these events will be computed 
along with a 95% confidence interval at day 100. Death and second transplant will be 
considered  as a competing risk in the estimation.  
[IP_ADDRESS].  Chronic GvHD  
The cumulative incidence  of patients who experience chronic GvHD will be computed 
along with a 95% confidence interval at [ADDRESS_668314] transplant . Death and 
second transplant will be considered as a competing risk in the estimation.  
[IP_ADDRESS].  Overall survival  
The proportion of patients alive at [ADDRESS_668315] transplant will be 
estimated using the Kaplan -Meier method.  
[IP_ADDRESS].  Safety and Tolerability of NiCord® Transplantation  
The safety and tolerability of NiCord® transplantation will be evaluated by [CONTACT_47972], 
incidenc e and frequency of adverse experiences and an estimation of the relationship to 
NiCord®, as well as infections and laboratory data follow -up, with special emphasis on 
safety of cell therapy, including the detection of infusion reactions, transmission of 
infections, new malignancies and autoimmune diseases.  
10.4.3.  Exploratory Endpoints  
[IP_ADDRESS].  Immune Reconstitution  
The distributions of total im munoglobulin levels at days 70, 100, 180, and 365  (mean, 
standard deviation, median, quartiles) will be estimated. The distributions of the numbers 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668316]® Single CBU Protocol   Page 92 
and proportions of different lympho cyte subpopulations at days 70, 100, 180, and 365  
(mean, standard deviation, median, quartiles) will also be estimated.  T he distributions of 
T-cell excision cir cles at days 100, 180, and 365  (mean, standard deviation, median, 
quartiles) will also be estimated.  P atients who have graft failure, who relapse, or who die 
before target day (70 , 100, 180, or 365  respectively) will  be excluded from this analysis.   
10.5. Missing Data   
Unless otherwise specified, patients with missing data will be excluded from the analysis 
in which their data is missing.  For descriptive analyses of multiple timepoints, patients 
with data missing at some timepoints but not others will be censored from the analysis of 
those timepoints in which their data is missing.  For survival and incidence curves 
patients with missing data will be included and censored at the time of missing data, 
unless otherwise speci fied as a competing risk.   
10.6. Analysis Plan Deviations   
Deviations from the original statistical analysis plan will be reported in the final study 
report.  
10.7. Statistical Software  
SAS® version 9.1 or higher software and R version 2.10.0 or higher will be used f or 
statistical analysis and data presentation of the information collected in this study.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668317]® Single CBU Protocol   Page 93 
11. CLINICAL DATA MANAGEMENT  
11.1. Data Quality Assurance   
This study will be organized, performed, and reported in compliance with the 
Sponsor/CRO’s SOPs, protocols and worki ng practice documents, and the requirements 
of the Declaration of Helsinki and ICH/GCP guidelines. Compliance will be achieved 
through a combination of study specific audits of investigative sites and audits at regular 
intervals of the Sponsor/CRO’s system s for data handling, analysis, and reporting.  
A quality assurance audit of this trial may be conducted by [CONTACT_4209]’s 
designees. The quality assurance auditor will have access to all medical records, the 
investigator’s trial -related files and correspondence, and the informed consent 
documentation that is relevant to this clinical trial.  
11.2. Data Collection   
Investigators or designees will enter the information required by [CONTACT_515661]. Each investigative site will be visited as frequently as documented in the 
monitoring plan by [CONTACT_515662]. The CRO representative will highlight any discrepancies 
found between source documents and the completed CRFs and ensure t hat appropriate 
site personnel address the discrepancies. When a discrepancy results in corrected CRF 
data, the correction will be reviewed again against the correct source documentation. 
Uniform procedures will be discussed at the Site Initiation Visit.  
11.3. Source Documents   
Source documents provide evidence for the existence of the patient and substantiate the 
integrity  of the data collected. All clinical data entered onto the CRF must be supported 
by [CONTACT_515663] .  Data entered in the CRFs that 
are transcribed from source documents must be consistent with the source documents or 
the discrepancies must be explained. The investigator may need to request previous 
medical records or transfer records, depending on the trial;  also current medical records 
must be available.  
Direct access to source data - documents  
• The investigator / institution will permit trial -related monitoring, audits, IRB / 
IEC review and regulatory inspection, providing direct access to all related source data / 
documents.  
• CRFs and all source documents, including progress notes and copi[INVESTIGATOR_331226]’s clinical 
trial monitor and inspection by [CONTACT_515664] (e.g. MS CA/EMA). The Clinical 
Research Associate (CRA) / on site monitor may review all CRFs, and written informed 
consents. The accuracy of the data will be verified by [CONTACT_331291].  
 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668318]® Single CBU Protocol   Page [ADDRESS_668319] safety, and adherence to guidelines in the Site Operations 
Manuals.  
At each site visit, the CRA will review recruitment guidelines and study eligibility 
criteria.  As the stud y progresses, completed data forms may be reviewed during site 
visits and compared to source documentation (medical or site records) to confirm 
accuracy.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668320]® Single CBU Protocol   Page 95 
APPENDIX A.  GVHD CLASSIFICATION  
 
Acute GvHD Definition  
Acute GvHD will be assessed at every visit  from transplanta tion (day 0) until end of 
study  or more frequently as clinically indicated. GvHD will be classified according to the 
Consensus Conference on Acute GvHD grading[52]: 
 
Overall Grade  Skin Liver  Gut 
I Stage 1 -2 None  None  
II Stage 3 or  Stage 1 or  Stage 1  
III  Stage 2 -3 or Stage 2 -4 
IV Stage 4 or  Stage 4   
 
*See following table for individual organ staging. The overall grade of GvHD, however, 
reflects the actual extent of disease. For each overall grade, an assessment of skin disease 
plus liver and/or gut involvement is required.  
 
Acute GvHD may be documented after day 99 (“late acute”) if according to clinical 
judgment the investigator feels it should be classified as acute rather than chronic.  
 
Clinical Manifestations and Staging of Acute Graft -versus -Host Disease  
Organ  Clinical Manifestations  Staging  
Skin Erythematous, maculopapular rash 
involving palms and soles; may 
become confluent  
Severe disease: bullae.  Stage 1: <25% rash  
Stage 2: 25 -50% rash  
Stage 3: generalized erythroderma  
Stage 4: bullae  
Liver  Painless jaundice with conjugated 
hyperbilirubinemia and increased 
alkaline phosphatase.  Stage 1: bilirubin 2 -3 mg/dL  
Stage 2: bilirubin 3.1 -6 mg/dL  
Stage 3: bilirubin 6.1 -15 mg/dL  
Stage 4: bilirubin >15 mg/dL  
Gastrointestinal tract  Upper: nausea, vomiting, anorex ia. 
Lower: diarrhea, abdominal cramps, 
distention, ileus, bleeding.  Stage 1: diarrhea >500 ml/day  or 
persistent nausea  
Stage 2: diarrhea >1000 ml/day  
Stage 3: diarrhea >1500 ml/day  
Stage 4: large volume diarrhea and 
severe abdominal pain +/ - ileus  
 
 
 
 
Chronic GvHD Definition  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668321]® Single CBU Protocol   Page [ADDRESS_668322] Disease  
Involvement  Clinical Criteria  
Limited  Localized skin involvement, liver dysfunction, or both.  
Extensive  Generalized skin involvement  
OR 
Localized skin involvement or liver dysfunction plus any one of the following:  
Chronic aggressive hepatitis, bridging necrosis, cirrhosis.  
Eye involvement (result on Schirmer test: <5 mm).  
Involvement of mucosalivary glands.  
Mucosal involvement (on lip biopsy).  
Involvement of other target organs.  
 Chronic GvHD will also be classified as mild, moderate, or severe, according to the 
National Institute of Health consensus grading criteria51. 
 
 
GC P# 03.01.020     Date : August [ADDRESS_668323]® Single CBU Protocol       Page 97 
APPENDIX B.  SAFETY DATA REPORTING  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* See appendix C for a list of common adverse events  
# With the exception of infections and GvHD symptoms which are reported on the Infection form and GvHD forms respectively.   During Conditioning 
up to Start of NiCord 
Infusion  During NiCord Infusion 
through [ADDRESS_668324] 
Infusion   
> [ADDRESS_668325] 
grade of all common* 
adverse events   
Complete a Toxicity form 
with the highest grade of all 
common* adverse events  
 
Grade 3 -5 events also require 
completion of SAE summary 
forms (AD1 -AD5)  
 
All grade [ADDRESS_668326] be 
listed in dividually on the 
Adverse Event Log form.# 
  
Complete a weekly Toxicity 
form with the highest grade 
of all common* adverse 
events during that week.  
 
Non-engraftment at day 42 
requires completion of SAE 
summary forms (AD1 -AD5)  
 
All other uncommon non -
seriou s adverse events must 
be listed individually on the 
Adverse Event Log form.# 
  
All grade [ADDRESS_668327] be listed 
individually on the 
Adverse Event Log 
form. # 
 
Infection form is required when applicable  
Scheduled  GvHD  data collection at every visit on either the GVH or the CGV form.  
Any event that also meets the definition of an SAE, requires submission of SAE summary forms (AD1 -AD5).  If the 
SAE is unexpected and associated with NiCord®, then an expedited report must be submitted.  
A Hospi[INVESTIGATOR_268497] (ADM) and/or Death form (DTH)  required if applicable  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668328]® Single CBU Protocol   Page 98 
APPENDIX C.  COMMON  ADVERSE EVENTS  
Cardiac  
Cardiac Arrhythmias  
 
Gastrointestinal  
Abdominal distension  
Nausea  
Vomiting  
Constipation  
Dyspepsia  
Dysphagia  
Mucositis  
 
General Disorders  
Allergic reaction  
Chills  
Edema  
Fatigue/Malaise/Lethargy  
Fever  
Pain  
 
Injury/Poi soning/Procedural Complications  
Bruising  
Hemorrhage  
Vascular access complications  
 
Investigations  
Elevated alkaline phosphatase  
Elevated creatinine  
Elevated liver transaminases (ALT, AST)  
Elevated triglycerides  
Weight loss  
 
Metabolism and Nutrition  
Abnormal sodium  
Anorexia  
Dehydration  
Hyperglycemia  
Hypokalemia  
Hypomagnesemia  
Hypophosphatemia  
Hypoalbuminemia  
 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668329]® Single CBU Protocol   Page 99 
Musculoskeletal  
 Generalized muscle weakness  
 
Neurologic  
Dizziness  
Dysgeusia  
Somnolence  
Syncope  
Tremors  
 
Psychiatric  
Anxiety  
Depression  
Insomnia  
 
Renal  
Non-infectious cystitis  
 
Respi[INVESTIGATOR_515628] P# 03.01.020   Date : August [ADDRESS_668330]® Single CBU Protocol   Page 100 
APPENDIX D.  COMMON TERMINOLOGY CRITERA FOR ADVERSE 
EVENTS V4.0 3  
(CTCAE)53  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668331]® Single CBU Protocol   Page 101 
APPENDIX E: DRUG LABELS  
 
See attached documents.  
 
 
GC P# 03.01.020   Date : August [ADDRESS_668332]® Single CBU Protocol   Page 102 
APPENDIX F: PROTOCOL AMENDMENT SUMMARY  
 
Protocol Version  Approved Sites  Main R eason (s) for 
Amendment  
Original  • Duke  University Medical 
Center  N/A 
Amendment I  • Duke  University Medical 
Center  Expand patient population 
and clarify eligibility criteria  
Amendment II  ▪ Cedars Sinai  Medical Center  
▪ Cleveland Clinic  
▪ Steven and Alexandra Cohen 
Children's Medical Center of 
[LOCATION_001]  
▪ Duke  University Medical 
Center  
▪ Vanderbilt  University Medical 
Center  Change in manufacturing 
procedure to cryopreserved 
product.   Modify eligibility 
criteria.  Additional option 
for conditioning regimen  
Amendment II.1  ▪ Hospi[INVESTIGATOR_331179] y 
Politécnico La Fe  Hospi[INVESTIGATOR_515629] d´Hebrón  
▪ Istituto Giannina Gaslini of 
Genoa  
▪ AOU San Luigi Gonzaga of 
Turin  Add safety objective .  Define 
childbearing potential and 
appropriate contraception.  
Amendment II.2  • University Medical Center 
Utrecht  Additional option for 
conditioning regimen.  
Amendment III  ▪ Cedars Sinai Medical Center  
▪ Cleveland Clinic  
▪ Steven and Alexandra Cohen 
Children's Medical Center of 
[LOCATION_001]  
▪ Duke University Medical 
Center  
▪ Vanderbilt University Medical 
Center  
▪ Hospi[INVESTIGATOR_331179] y 
Politécnico La Fe  
▪ Hospi[INVESTIGATOR_70218] 
d´Hebrón  Modify eligibility criteria.  
Additional regimen specific 
stoppi[INVESTIGATOR_15381].  
Additional supportive and 
viral monitoring care 
guidelines.  Update AE 
reporting guidelines.  
Amendment IV  ▪ Cedars Sinai Medical Center  
▪ Cleveland Clinic  
▪ Steven and Alexandra Cohen 
Children's Medical Center of 
[LOCATION_001]  Increase number of patients 
for study enrollment, modify 
eligibility criteria, COA 
release criteria, GvHD 
prophylaxis medicat ion 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668333]® Single CBU Protocol   Page 103 
▪ Duke University M edical 
Center  
▪ Vanderbilt University Medical 
Center  
▪ Hospi[INVESTIGATOR_331179] y 
Politécnico La Fe  
▪ Hospi[INVESTIGATOR_70218] 
d´Hebrón  administration and 
assessment grading criteria,  
 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668334]® Single CBU Protocol   Page 104 
REFERENCES  
 
1. 1 Cottler -Fox, M. H., T. Lapi[INVESTIGATOR_148595], et al. (2003). "Stem cell mobilization." Hematology Am Soc 
Hematol Educ Program : 419 -437. 
 
2. 2 Wagner, J. E. (2009). "Should double cord blood transplants be the preferred choice when a 
sibling donor is unavailable?" Best Pract Res Clin Haematol  22(4): 551 -555. 
 
3. 3 Aljitawi, O. S. (2012). "Ex vivo expansion of umbilical cord blood: where are we?" Int J 
Hematol  95(4): 371 -379. 
 
4. 4 Yamazaki, R., M. Kuwana, et al. (2006). "Prolonged thrombocytopenia after allogeneic 
hematopoietic stem cell transplantation: associations with impaired platelet production and 
increased platelet turnover." Bone Marrow Transpl ant 38(5): 377 -384. 
 
5. 5 Brunstein, C. G., J. A. Gutman, et al. (2010). "Allogeneic hematopoietic cell transplantation for 
hematological malignancy: relative risks and benefits of double umbilical cord blood." Blood . 
 
6. 6 Ramirez, P., C. G. Brunstein, et al. ( 2010). "Delayed platelet recovery after allogeneic 
transplantation: a predictor of increased treatment -related mortality and poorer survival." Bone 
Marrow Transplant . 
 
7. 7 MacMillan, M. L., D. J. Weisdorf, et al. (2009). "Acute graft -versus -host disease afte r unrelated 
donor umbilical cord blood transplantation: analysis of risk factors." Blood  113(11): 2410 -2415.  
 
8. 8 Stanevsky, A., A. Shimoni, et al. (2010). "Double umbilical cord blood transplant: more than a 
cell dose?" Leuk Lymphoma . 
9. 9 Verneris, M. R., C. G. Brunstein, et al. (2009). "Relapse risk after umbilical cord blood 
transplantation: enhanced graft -versus -leukemia effect in recipi[INVESTIGATOR_22880] 2 units." Blood  
114(19): 4293 -4299.  
 
10 Sideri, A., N. Neokleous, et al. (2011). “An overview o f the progress on double umbilical cord 
blood transplantation.” Haematologica  96(8): 1213 -1220.  
 
10. 11 Scaradavou, A., K. M. Smith, et al. (2009). "Cord Blood Units with Low CD34+ Cell Viability 
Have a Low Probability of Engraftment After Double Unit Transplan tation." Biol Blood Marrow 
Transplant . 
 
12 Ramirez, P., J. E. Wagner, et al. (2012). "Factors predicting single -unit predominance after double 
umbilical cord blood transplantation." Bone Marrow Transplant  47(6): 799 -803. 
11. 13 Majhail, N. S., C. G. Brunstein, et al. (2006). "Double umbilical cord blood  transplantation." 
Curr Opin Immunol  18(5): 571 -575. 
 
14 Newell, L. F., F. Milano, et al. (2012). "Early CD3 Peripheral Blood Chimerism Predicts the Long -Term 
Engrafting Unit Following Myeloablative Double -Cord Blood Transplantation." Biol Blood 
Marrow Tran splant . 
12. 15 Eldjerou, L. K., S. Chaudhury, et al. (2010). "An in vivo model of double -unit cord blood 
transplantation that correlates with clinical engraftment." Blood  116(19): 3999 -4006.  
 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668335]® Single CBU Protocol   Page 105 
 
13. 16 Moretta, A., G. Andriolo, et al. (2012). "In Vitro Evaluation of Gr aft-versus -Graft 
Alloreactivity as a Tool to Identify the Predominant Cord Blood Unit before Double Cord Blood 
Transplantation." Biol Blood Marrow Transplant  18(7): 1108 -1118.  
 
17 Kelly, S. S., S. Parmar, et al. (2010). "Overcoming the barriers to umbilical  cord blood transplantation." 
Cytotherapy  12(2): 121 -130. 
14. 18 Dahlberg, A., C. Delaney, et al. (2011). "Ex vivo expansion of human hematopoietic stem and 
progenitor cells." Blood  117(23): 6083 -6090.  
 
15. 19 Delaney, C., M. Z. Ratajczak, et al. (2010). "Strategies to enhance umbilical cord blood stem 
cell engraftment in ad ult patients." Expert Rev Hematol  3(3): 273 -283. 
 
16. 20 De Lima, M., S. Robinson, et al. (2010). "Mesenchymal Stem Cell (MSC) Based Cord Blood 
(CB) Expansion (Exp) Leads to Rapid Engraftment of Platelets and Neutrophils." ASH Annual 
Meeting Abstracts  116(21): 362-. 
 
[ADDRESS_668336] -blood engraftment with ex vivo mesenchymal -cell coculture.  N 
Engl J Med. 2012 Dec 13;367(24):2305 -15. 
 
17. 22 Srour, E. F., R. Abonour, et al. (1999). "Ex vivo expansion of hematopoietic stem and 
progenitor cells: are we there yet?" J Hematother  8(2): 93 -102. 
 
18. 23 Ando, K., T. Yahata, et al. (2006). "Direct evidence for ex vivo expansion of human 
hematopoietic stem cells." Blood  107(8): 3371 -3377.  
 
19. 24 Drake, A. C., M. Khoury, et al. (2011). "Human CD34+ CD133+ hematopoietic stem cells 
cultured with growth factors including Angptl5 efficiently engraft adult NOD -SCID Il2rgamma -/- 
(NSG) mice." PLoS ONE  6(4): e18382.  
 
20. 25 Holmes, T., F. Yan, et al. (2012). "Ex vivo expansion of cord blood progenitors impairs their 
short -term and long -term repopulating activity associated with transcriptional dysregulation of 
signalling networks." Cell Prolif  45(3): 266 -278. 
 
26 Szilvassy SJ, Bass MJ, Van Zant G, Grimes B. Organ -selective homing defines engraftment kinetics of 
murine hematopoietic stem cells and is compromised by [CONTACT_331295]. Blood. Mar 1 
1999;93(5):1557 -1566.  
 
27 Ahmed F, Ings SJ, Pi[INVESTIGATOR_515630], Blundell MP, Thr asher AJ, et al. (2004) Impaired bone marrow homing 
of cytokine -activated CD34+ cells in the NOD/SCID model. Blood 103: 2079 –2087 
 
28 Foguenne J, Huygen S, Greimers R, Beguin Y, Gothot A. Modulation of homing properties of primitive 
progenitor cells generat ed by [CONTACT_331296]. Haematologica. Apr 2005;90(4):445 -451 
 
29 Von Drygalski A, Alespeiti G, Ren L, Adamson JW. Murine bone marrow cells cultured ex vivo in the 
presence of multiple cytokine combinations lose radioprotective and long -term engraftment 
potential. Stem cells and development. Feb 2004;13(1):[ADDRESS_668337] blood progeny cells that retain a CD34+ phenotype after ex vivo 
expansion have less engraftment potential than unexpanded CD34+ cells. Transfusion. Feb 
2001;41(2):213 -218. 
 
31Szilvassy SJ, Meyerrose TE, Grimes B. Effects of cel l cycle activation on the short -term engraftment 
properties of ex vivo expanded murine hematopoietic cells. Blood. May 1 2000;95(9):2829 -2837.   
 
 
GC P# 03.01.020   Date : August [ADDRESS_668338]® Single CBU Protocol   Page [ADDRESS_668339]. Aug 2001;108(3):[ADDRESS_668340] blood stem 
cells for transplantation: growing knowledge from the hematopoietic niche. Bone Marrow 
Transplant. Jan 2007;39(1):11 -23. 
 
34 Peled T, Shoham H, Aschengrau D, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and 
facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow ho ming and 
engraftment. Experimental Hematology. Apr 2012;40(4):342 -355 e341.  
 
35 Berger, F., Ramírez -Hernández, M. H. and Ziegler, M. (2004) The new life of a centenarian: signalling 
functions of NAD(P). Trends Biochem. Sci. 29, 111 –118 
 
36 Banasik M, Komura H, Shimoyama M, and Ueda K (1992) Specific inhibitors of poly(ADP -ribose) 
synthetase and mono(ADP -ribosyl)transferase. J Biol Chem 267: 1569 –1575.  
 
37Corda D, Di Girolamo M. Functional aspects of protein mono -ADP -ribosylation. Embo J. May 1 
2003;22(9):1953 -1958.  
 
38 Krebs C, Adriouch S, Braasch F, et al. CD38 controls ADP -ribosyltransferase -2-catalyzed ADP -
ribosylation of T cell surface proteins. J Immunol. Mar 15 2005;174(6):3298 -3305.  
 
39 Glowacki G, Braren R, Firner K, et al. The family of toxin -related ecto -ADP -ribosyltransferases in 
humans and the mouse. Protein science : a publication of the Protein Society. Jul 
2002;11(7):1657 -1670.  
 
40 Papaccio G, Ammendola E, Pi[INVESTIGATOR_515631]. Nicotinamide decreases MHC class II but not MHC class I 
expression  and increases intercellular adhesion molecule -1 structures in non -obese diabetic mouse 
pancreas. The Journal of endocrinology. Mar 1999;160(3):389 -400. 
 
41 Sato F, Mitaka T, Mizuguchi T, Mochizuki Y, Hirata K. Effects of nicotinamide -related agents on the 
growth of primary rat hepatocytes and formation of small hepatocyte colonies. Liver. Dec 
1999;19(6):481 -488. 
 
42 Miura M, Kameda Y. Nicotinamide promotes long -term survival and extensive neurite outgrowth in 
ultimobranchia l C cells cultured from chick embryos. The Journal of comparative neurology. Nov 
21 2005;492(3):334 -348. 
 
43 Munshi CB, Graeff R, Lee HC. Evidence for a causal role of CD38 expression in granulocytic 
differentiation of human HL -60 cells. J Biol Chem. Dec 20  2002;277(51):[ZIP_CODE] -[ZIP_CODE].  
 
44Iwata K, Ogata S, Okumura K, Taguchi H. Induction of differentiation in human promyelocytic leukemia 
HL-60 cell line by [CONTACT_331297] -related compounds. Bioscience, biotechnology, and biochemistry. May 
2003;67(5):[ADDRESS_668341] 
2005;9(5):431 -440. 
 
 
 
GC P# 03.01.020   Date : August [ADDRESS_668342]® Single CBU Protocol   Page [ADDRESS_668343] Sir2 and 
human SIRT1. J. Biol. Chem. 277: [ZIP_CODE] –[ZIP_CODE]  
 
47 Vaca P, Berna G, Martin F, Soria B. Nicotinamide induces both proliferation and differentiation of 
embryonic stem cells into insulin -producing cells. Transplant Proc. Aug 2003;35(5):[ADDRESS_668344] Dermatol. 2009 Jan;129(1):41 -9. Epub 2008 Jun 19.  
 
49 Kim MJ, Ahn K, Park SH, et al. SIRT1 regulates tyrosine hydroxylase expression and differentiation of 
neuroblastoma cells via FOXO3a. FEBS Lett. Apr 2 2009;583(7):1183 -1188.  
 
50 Bartelink I, et al (2012). “Body Weight -Dependent Pharmacokinetics of Busulfan  in Paediatric 
Haematopoietic Stem Cell Tranplantation Patients.” Clin Pharmacokinet  51(5); [ADDRESS_668345] Disease: I. Diagnosis and Staging Working Group 
Report Biology of Blood and Marrow Transplant .  Dec 2005;  11(12): 945–956 
 
52 Przep iorka D, Weisdorf D, et al.  Meeting Report: Consensus Conference on Acute GvHD Grading.  
Bone Marrow Transplantation.  1995; 15: 825 -828  
 
53 Cancer Therapy Evaluation, D., NCI, NIH, DHHS (2009). "Common Terminology Criteria for Adverse 
Events v4.0 (CTCAE).  